Trial Outcomes & Findings for A Study of Atezolizumab in Combination With Carboplatin or Cisplatin + Pemetrexed Compared With Carboplatin or Cisplatin + Pemetrexed in Participants Who Are Chemotherapy-Naive and Have Stage IV Non-Squamous Non-Small Cell Lung Cancer (NSCLC) (IMpower 132) (NCT NCT02657434)

Last Updated: 2023-11-21

Results Overview

PFS is defined as the time from randomization to the first occurrence of disease progression as determined by the investigator using RECIST v1.1 or death from any cause, whichever occurred first.

Recruitment status

COMPLETED

Study phase

PHASE3

Target enrollment

578 participants

Primary outcome timeframe

Randomization up to approximately 39 months

Results posted on

2023-11-21

Participant Flow

The study is considered "Completed" because the planned study activities and analyses have been performed.

Participant milestones

Participant milestones
Measure	Arm B (Carboplatin or Cisplatin + Pemetrexed) Participants received IV infusion of 500 mg/m\^2 pemetrexed on Day 1 q3w, and as per investigator's choice of either IV infusion of carboplatin on Day 1 q3w with a dose calculated using 'Calvert formula' to obtain AUC =6 mg/mL/min or IV infusion of 75 mg/m\^2 cisplatin q3w on Day 1 q3w, during induction dosing period for 4 or 6 cycles (Cycle length=21 days). Participants who did not experience disease progression during the induction phase began maintenance therapy. Participants will receive IV infusion of 500 mg/m\^2 of pemetrexed on Day 1 q3w until disease progression in the maintenance period.	Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed Participants received intravenous (IV) infusion of 1200 milligrams (mg) of atezolizumab on Day 1 every 3 weeks (q3w), IV infusion of 500 milligrams per meter square (mg/m\^2) pemetrexed on Day 1 q3w, and as per investigator's choice either IV infusion of carboplatin on Day 1 q3w with a dose calculated using 'Calvert formula' to obtain area under concentration versus time (AUC) = 6 milligrams per milliliter per minute (mg/mL/min) or IV infusion of 75 mg/m\^2 cisplatin q3w on Day 1 q3w, during induction dosing period of 4 or 6 cycles (Cycle length=21 days). Participants who experienced clinical benefit during the induction phase began maintenance therapy. Participants will receive IV infusion of 1200 mg of atezolizumab and 500 mg/m\^2 of pemetrexed on Day 1 q3w until disease progression in the maintenance period.
Overall Study STARTED	286	292
Overall Study COMPLETED	0	0
Overall Study NOT COMPLETED	286	292

Reasons for withdrawal

Reasons for withdrawal
Measure	Arm B (Carboplatin or Cisplatin + Pemetrexed) Participants received IV infusion of 500 mg/m\^2 pemetrexed on Day 1 q3w, and as per investigator's choice of either IV infusion of carboplatin on Day 1 q3w with a dose calculated using 'Calvert formula' to obtain AUC =6 mg/mL/min or IV infusion of 75 mg/m\^2 cisplatin q3w on Day 1 q3w, during induction dosing period for 4 or 6 cycles (Cycle length=21 days). Participants who did not experience disease progression during the induction phase began maintenance therapy. Participants will receive IV infusion of 500 mg/m\^2 of pemetrexed on Day 1 q3w until disease progression in the maintenance period.	Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed Participants received intravenous (IV) infusion of 1200 milligrams (mg) of atezolizumab on Day 1 every 3 weeks (q3w), IV infusion of 500 milligrams per meter square (mg/m\^2) pemetrexed on Day 1 q3w, and as per investigator's choice either IV infusion of carboplatin on Day 1 q3w with a dose calculated using 'Calvert formula' to obtain area under concentration versus time (AUC) = 6 milligrams per milliliter per minute (mg/mL/min) or IV infusion of 75 mg/m\^2 cisplatin q3w on Day 1 q3w, during induction dosing period of 4 or 6 cycles (Cycle length=21 days). Participants who experienced clinical benefit during the induction phase began maintenance therapy. Participants will receive IV infusion of 1200 mg of atezolizumab and 500 mg/m\^2 of pemetrexed on Day 1 q3w until disease progression in the maintenance period.
Overall Study Study Terminated By Sponsor	64	82
Overall Study Death	189	190
Overall Study Lost to Follow-up	2	2
Overall Study Randomization by Error	2	0
Overall Study Withdrawal by Subject	28	17
Overall Study Protocol Violation	1	0
Overall Study Physician Decision	0	1

Baseline Characteristics

A Study of Atezolizumab in Combination With Carboplatin or Cisplatin + Pemetrexed Compared With Carboplatin or Cisplatin + Pemetrexed in Participants Who Are Chemotherapy-Naive and Have Stage IV Non-Squamous Non-Small Cell Lung Cancer (NSCLC) (IMpower 132)

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure	Arm B (Carboplatin or Cisplatin + Pemetrexed) n=286 Participants Participants received IV infusion of 500 mg/m\^2 pemetrexed on Day 1 q3w, and as per investigator's choice of either IV infusion of carboplatin on Day 1 q3w with a dose calculated using 'Calvert formula' to obtain AUC =6 mg/mL/min or IV infusion of 75 mg/m\^2 cisplatin q3w on Day 1 q3w, during induction dosing period for 4 or 6 cycles (Cycle length=21 days). Participants who did not experience disease progression during the induction phase will begin maintenance therapy. Participants will receive IV infusion of 500 mg/m\^2 of pemetrexed on Day 1 q3w until disease progression in the maintenance period.	Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed n=292 Participants Participants received intravenous (IV) infusion of 1200 milligrams (mg) of atezolizumab on Day 1 every 3 weeks (q3w), IV infusion of 500 milligrams per meter square (mg/m\^2) pemetrexed on Day 1 q3w, and as per investigator's choice either IV infusion of carboplatin on Day 1 q3w with a dose calculated using 'Calvert formula' to obtain area under concentration versus time (AUC) = 6 milligrams per milliliter per minute (mg/mL/min) or IV infusion of 75 mg/m\^2 cisplatin q3w on Day 1 q3w, during induction dosing period of 4 or 6 cycles (Cycle length=21 days). Participants who experienced clinical benefit during the induction phase began maintenance therapy. Participants will receive IV infusion of 1200 mg of atezolizumab and 500 mg/m\^2 of pemetrexed on Day 1 q3w until disease progression in the maintenance period.	Total n=578 Participants Total of all reporting groups
Age, Continuous	61.8 Years STANDARD_DEVIATION 9.4 • n=5 Participants	63.3 Years STANDARD_DEVIATION 9.4 • n=7 Participants	62.6 Years STANDARD_DEVIATION 9.4 • n=5 Participants
Sex: Female, Male Female	94 Participants n=5 Participants	100 Participants n=7 Participants	194 Participants n=5 Participants
Sex: Female, Male Male	192 Participants n=5 Participants	192 Participants n=7 Participants	384 Participants n=5 Participants
Ethnicity (NIH/OMB) Hispanic or Latino	21 Participants n=5 Participants	17 Participants n=7 Participants	38 Participants n=5 Participants
Ethnicity (NIH/OMB) Not Hispanic or Latino	241 Participants n=5 Participants	243 Participants n=7 Participants	484 Participants n=5 Participants
Ethnicity (NIH/OMB) Unknown or Not Reported	24 Participants n=5 Participants	32 Participants n=7 Participants	56 Participants n=5 Participants
Race (NIH/OMB) American Indian or Alaska Native	1 Participants n=5 Participants	1 Participants n=7 Participants	2 Participants n=5 Participants
Race (NIH/OMB) Asian	65 Participants n=5 Participants	71 Participants n=7 Participants	136 Participants n=5 Participants
Race (NIH/OMB) Native Hawaiian or Other Pacific Islander	0 Participants n=5 Participants	0 Participants n=7 Participants	0 Participants n=5 Participants
Race (NIH/OMB) Black or African American	4 Participants n=5 Participants	2 Participants n=7 Participants	6 Participants n=5 Participants
Race (NIH/OMB) White	203 Participants n=5 Participants	193 Participants n=7 Participants	396 Participants n=5 Participants
Race (NIH/OMB) More than one race	0 Participants n=5 Participants	0 Participants n=7 Participants	0 Participants n=5 Participants
Race (NIH/OMB) Unknown or Not Reported	13 Participants n=5 Participants	25 Participants n=7 Participants	38 Participants n=5 Participants

PRIMARY outcome

Timeframe: Randomization up to approximately 39 months

Population: The ITT population was defined as all randomized patients, whether or not the patients received the assigned treatment.

PFS is defined as the time from randomization to the first occurrence of disease progression as determined by the investigator using RECIST v1.1 or death from any cause, whichever occurred first.

Outcome measures

Outcome measures
Measure	Arm B (Carboplatin or Cisplatin + Pemetrexed) n=286 Participants Participants received IV infusion of 500 mg/m\^2 pemetrexed on Day 1 q3w, and as per investigator's choice of either IV infusion of carboplatin on Day 1 q3w with a dose calculated using 'Calvert formula' to obtain AUC =6 mg/mL/min or IV infusion of 75 mg/m\^2 cisplatin q3w on Day 1 q3w, during induction dosing period for 4 or 6 cycles (Cycle length=21 days). Participants who did not experience disease progression during the induction phase began maintenance therapy. Participants will receive IV infusion of 500 mg/m\^2 of pemetrexed on Day 1 q3w until disease progression in the maintenance period.	Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed n=292 Participants Participants received intravenous (IV) infusion of 1200 milligrams (mg) of atezolizumab on Day 1 every 3 weeks (q3w), IV infusion of 500 milligrams per meter square (mg/m\^2) pemetrexed on Day 1 q3w, and as per investigator's choice either IV infusion of carboplatin on Day 1 q3w with a dose calculated using 'Calvert formula' to obtain area under concentration versus time (AUC) = 6 milligrams per milliliter per minute (mg/mL/min) or IV infusion of 75 mg/m\^2 cisplatin q3w on Day 1 q3w, during induction dosing period of 4 or 6 cycles (Cycle length=21 days). Participants who experienced clinical benefit during the induction phase began maintenance therapy. Participants will receive IV infusion of 1200 mg of atezolizumab and 500 mg/m\^2 of pemetrexed on Day 1 q3w until disease progression in the maintenance period.
Progression Free Survival (PFS) as Assessed by the Investigator Using Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1)	5.2 Months Interval 4.3 to 5.6	7.7 Months Interval 6.7 to 8.5

PRIMARY outcome

Timeframe: Randomization up to approximately 39 months

Population: The ITT population was defined as all randomized patients, whether or not the patients received the assigned treatment.

OS is defined as time from randomization to death from any cause.

Outcome measures

Outcome measures
Measure	Arm B (Carboplatin or Cisplatin + Pemetrexed) n=286 Participants Participants received IV infusion of 500 mg/m\^2 pemetrexed on Day 1 q3w, and as per investigator's choice of either IV infusion of carboplatin on Day 1 q3w with a dose calculated using 'Calvert formula' to obtain AUC =6 mg/mL/min or IV infusion of 75 mg/m\^2 cisplatin q3w on Day 1 q3w, during induction dosing period for 4 or 6 cycles (Cycle length=21 days). Participants who did not experience disease progression during the induction phase began maintenance therapy. Participants will receive IV infusion of 500 mg/m\^2 of pemetrexed on Day 1 q3w until disease progression in the maintenance period.	Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed n=292 Participants Participants received intravenous (IV) infusion of 1200 milligrams (mg) of atezolizumab on Day 1 every 3 weeks (q3w), IV infusion of 500 milligrams per meter square (mg/m\^2) pemetrexed on Day 1 q3w, and as per investigator's choice either IV infusion of carboplatin on Day 1 q3w with a dose calculated using 'Calvert formula' to obtain area under concentration versus time (AUC) = 6 milligrams per milliliter per minute (mg/mL/min) or IV infusion of 75 mg/m\^2 cisplatin q3w on Day 1 q3w, during induction dosing period of 4 or 6 cycles (Cycle length=21 days). Participants who experienced clinical benefit during the induction phase began maintenance therapy. Participants will receive IV infusion of 1200 mg of atezolizumab and 500 mg/m\^2 of pemetrexed on Day 1 q3w until disease progression in the maintenance period.
Overall Survival (OS)	13.6 Months Interval 11.0 to 15.7	17.5 Months Interval 13.2 to 19.6

SECONDARY outcome

Timeframe: Year 1

Population: The ITT population was defined as all randomized patients, whether or not the patients received the assigned treatment.

The Overall Survival Rate at the 1-year landmark time point is defined as the probabilities that participants are alive 1-year after randomization.

Outcome measures

Outcome measures
Measure	Arm B (Carboplatin or Cisplatin + Pemetrexed) n=286 Participants Participants received IV infusion of 500 mg/m\^2 pemetrexed on Day 1 q3w, and as per investigator's choice of either IV infusion of carboplatin on Day 1 q3w with a dose calculated using 'Calvert formula' to obtain AUC =6 mg/mL/min or IV infusion of 75 mg/m\^2 cisplatin q3w on Day 1 q3w, during induction dosing period for 4 or 6 cycles (Cycle length=21 days). Participants who did not experience disease progression during the induction phase began maintenance therapy. Participants will receive IV infusion of 500 mg/m\^2 of pemetrexed on Day 1 q3w until disease progression in the maintenance period.	Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed n=292 Participants Participants received intravenous (IV) infusion of 1200 milligrams (mg) of atezolizumab on Day 1 every 3 weeks (q3w), IV infusion of 500 milligrams per meter square (mg/m\^2) pemetrexed on Day 1 q3w, and as per investigator's choice either IV infusion of carboplatin on Day 1 q3w with a dose calculated using 'Calvert formula' to obtain area under concentration versus time (AUC) = 6 milligrams per milliliter per minute (mg/mL/min) or IV infusion of 75 mg/m\^2 cisplatin q3w on Day 1 q3w, during induction dosing period of 4 or 6 cycles (Cycle length=21 days). Participants who experienced clinical benefit during the induction phase began maintenance therapy. Participants will receive IV infusion of 1200 mg of atezolizumab and 500 mg/m\^2 of pemetrexed on Day 1 q3w until disease progression in the maintenance period.
Overall Survival Rate at Year 1	55.04 Percentage Interval 49.21 to 60.87	59.72 Percentage Interval 54.02 to 65.41

SECONDARY outcome

Timeframe: Year 2

The Overall Survival Rate at the 2-year landmark time point is defined as the probabilities that participants are alive 2-years after randomization.

Outcome measures

Outcome measures
Measure	Arm B (Carboplatin or Cisplatin + Pemetrexed) n=286 Participants Participants received IV infusion of 500 mg/m\^2 pemetrexed on Day 1 q3w, and as per investigator's choice of either IV infusion of carboplatin on Day 1 q3w with a dose calculated using 'Calvert formula' to obtain AUC =6 mg/mL/min or IV infusion of 75 mg/m\^2 cisplatin q3w on Day 1 q3w, during induction dosing period for 4 or 6 cycles (Cycle length=21 days). Participants who did not experience disease progression during the induction phase began maintenance therapy. Participants will receive IV infusion of 500 mg/m\^2 of pemetrexed on Day 1 q3w until disease progression in the maintenance period.	Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed n=292 Participants Participants received intravenous (IV) infusion of 1200 milligrams (mg) of atezolizumab on Day 1 every 3 weeks (q3w), IV infusion of 500 milligrams per meter square (mg/m\^2) pemetrexed on Day 1 q3w, and as per investigator's choice either IV infusion of carboplatin on Day 1 q3w with a dose calculated using 'Calvert formula' to obtain area under concentration versus time (AUC) = 6 milligrams per milliliter per minute (mg/mL/min) or IV infusion of 75 mg/m\^2 cisplatin q3w on Day 1 q3w, during induction dosing period of 4 or 6 cycles (Cycle length=21 days). Participants who experienced clinical benefit during the induction phase began maintenance therapy. Participants will receive IV infusion of 1200 mg of atezolizumab and 500 mg/m\^2 of pemetrexed on Day 1 q3w until disease progression in the maintenance period.
Overall Survival Rate Year 2	34.01 Percentage Interval 28.4 to 39.62	39.13 Percentage Interval 33.44 to 44.81

SECONDARY outcome

Timeframe: Randomization up to approximately 25 months

Population: The ITT population was defined as all randomized patients, whether or not the patients received the assigned treatment.

An objective response is defined as either an unconfirmed CR or a PR, as determined by the investigator using RECIST v1.1. Objective Response Rate is defined as the proportion of patients who had an objective response.

Outcome measures

Outcome measures
Measure	Arm B (Carboplatin or Cisplatin + Pemetrexed) n=286 Participants Participants received IV infusion of 500 mg/m\^2 pemetrexed on Day 1 q3w, and as per investigator's choice of either IV infusion of carboplatin on Day 1 q3w with a dose calculated using 'Calvert formula' to obtain AUC =6 mg/mL/min or IV infusion of 75 mg/m\^2 cisplatin q3w on Day 1 q3w, during induction dosing period for 4 or 6 cycles (Cycle length=21 days). Participants who did not experience disease progression during the induction phase began maintenance therapy. Participants will receive IV infusion of 500 mg/m\^2 of pemetrexed on Day 1 q3w until disease progression in the maintenance period.	Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed n=292 Participants Participants received intravenous (IV) infusion of 1200 milligrams (mg) of atezolizumab on Day 1 every 3 weeks (q3w), IV infusion of 500 milligrams per meter square (mg/m\^2) pemetrexed on Day 1 q3w, and as per investigator's choice either IV infusion of carboplatin on Day 1 q3w with a dose calculated using 'Calvert formula' to obtain area under concentration versus time (AUC) = 6 milligrams per milliliter per minute (mg/mL/min) or IV infusion of 75 mg/m\^2 cisplatin q3w on Day 1 q3w, during induction dosing period of 4 or 6 cycles (Cycle length=21 days). Participants who experienced clinical benefit during the induction phase began maintenance therapy. Participants will receive IV infusion of 1200 mg of atezolizumab and 500 mg/m\^2 of pemetrexed on Day 1 q3w until disease progression in the maintenance period.
Percentage of Participants With an Objective Response (Complete Response [CR] or Partial Response [PR]) Assessed by the Investigator Using RECIST V1.1 Responders	37.4 Percentage of Participants	51.7 Percentage of Participants
Percentage of Participants With an Objective Response (Complete Response [CR] or Partial Response [PR]) Assessed by the Investigator Using RECIST V1.1 Non-Responders	62.6 Percentage of Participants	48.3 Percentage of Participants

SECONDARY outcome

Timeframe: Randomization up to approximately 25 months

Population: DOR was assessed in participants who had an objective response as determined by the investigator using RECIST v1.1.

DOR is defined as the time interval from the date of the first occurrence of a CR or PR (whichever status is recorded first) until the first date that progressive disease or death is documented, whichever occurs first.

Outcome measures

Outcome measures
Measure	Arm B (Carboplatin or Cisplatin + Pemetrexed) n=286 Participants Participants received IV infusion of 500 mg/m\^2 pemetrexed on Day 1 q3w, and as per investigator's choice of either IV infusion of carboplatin on Day 1 q3w with a dose calculated using 'Calvert formula' to obtain AUC =6 mg/mL/min or IV infusion of 75 mg/m\^2 cisplatin q3w on Day 1 q3w, during induction dosing period for 4 or 6 cycles (Cycle length=21 days). Participants who did not experience disease progression during the induction phase began maintenance therapy. Participants will receive IV infusion of 500 mg/m\^2 of pemetrexed on Day 1 q3w until disease progression in the maintenance period.	Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed n=292 Participants Participants received intravenous (IV) infusion of 1200 milligrams (mg) of atezolizumab on Day 1 every 3 weeks (q3w), IV infusion of 500 milligrams per meter square (mg/m\^2) pemetrexed on Day 1 q3w, and as per investigator's choice either IV infusion of carboplatin on Day 1 q3w with a dose calculated using 'Calvert formula' to obtain area under concentration versus time (AUC) = 6 milligrams per milliliter per minute (mg/mL/min) or IV infusion of 75 mg/m\^2 cisplatin q3w on Day 1 q3w, during induction dosing period of 4 or 6 cycles (Cycle length=21 days). Participants who experienced clinical benefit during the induction phase began maintenance therapy. Participants will receive IV infusion of 1200 mg of atezolizumab and 500 mg/m\^2 of pemetrexed on Day 1 q3w until disease progression in the maintenance period.
Duration of Response (DOR) as Determined by the Investigator Using RECIST v1.1	6.4 Months Interval 4.4 to 7.6	9.5 Months Interval 6.9 to 12.2

SECONDARY outcome

Timeframe: Baseline up to 3 and 6 months after disease progression or loss of clinical benefit (up to approximately 25 months)

Population: ITT population with a non-missing baseline and at least a post-baseline PRO assessment (i.e., PRO evaluable population).

EORTC QLQ-C30 is a validated and reliable self-report measure that consists of 30 questions that assess five aspects of patient functioning (physical, emotional, role, cognitive, and social), three symptom scales (fatigue, nausea and vomiting, pain), global health/quality of life, and six single items (dyspnea, insomnia, appetite loss, constipation, diarrhea, and financial difficulties). EORTC QLQ-C30 is scored according to the EORTC scoring manual (Fayers et al. 2001). All EORTC scales and single-item measures are linearly transformed so that each score has a range of 0-100. A high score for a functional/global health status scale represents a high or healthy level of functioning/HRQoL (Health-Related Quality of Life); however a high score for a symptom scale or item represents a high level of symptomatology or problems. A ≥10-point change in the symptoms subscale score is perceived by patients as clinically significant (Osoba et al. 1998).

Outcome measures

Outcome measures
Measure	Arm B (Carboplatin or Cisplatin + Pemetrexed) n=232 Participants Participants received IV infusion of 500 mg/m\^2 pemetrexed on Day 1 q3w, and as per investigator's choice of either IV infusion of carboplatin on Day 1 q3w with a dose calculated using 'Calvert formula' to obtain AUC =6 mg/mL/min or IV infusion of 75 mg/m\^2 cisplatin q3w on Day 1 q3w, during induction dosing period for 4 or 6 cycles (Cycle length=21 days). Participants who did not experience disease progression during the induction phase began maintenance therapy. Participants will receive IV infusion of 500 mg/m\^2 of pemetrexed on Day 1 q3w until disease progression in the maintenance period.	Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed n=242 Participants Participants received intravenous (IV) infusion of 1200 milligrams (mg) of atezolizumab on Day 1 every 3 weeks (q3w), IV infusion of 500 milligrams per meter square (mg/m\^2) pemetrexed on Day 1 q3w, and as per investigator's choice either IV infusion of carboplatin on Day 1 q3w with a dose calculated using 'Calvert formula' to obtain area under concentration versus time (AUC) = 6 milligrams per milliliter per minute (mg/mL/min) or IV infusion of 75 mg/m\^2 cisplatin q3w on Day 1 q3w, during induction dosing period of 4 or 6 cycles (Cycle length=21 days). Participants who experienced clinical benefit during the induction phase began maintenance therapy. Participants will receive IV infusion of 1200 mg of atezolizumab and 500 mg/m\^2 of pemetrexed on Day 1 q3w until disease progression in the maintenance period.
Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by European Organization for the Research and Treatment of Cancer (EORTC) Quality-of-Life Questionnaire-Core 30 (QLQ-C30) Symptom Score Dyspnoea: Week 3	-1.95 Units on a scale Standard Deviation 23.97	-1.39 Units on a scale Standard Deviation 25.17
Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by European Organization for the Research and Treatment of Cancer (EORTC) Quality-of-Life Questionnaire-Core 30 (QLQ-C30) Symptom Score Dyspnoea: Week 6	-1.23 Units on a scale Standard Deviation 23.16	-4.71 Units on a scale Standard Deviation 26.66
Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by European Organization for the Research and Treatment of Cancer (EORTC) Quality-of-Life Questionnaire-Core 30 (QLQ-C30) Symptom Score Dyspnoea: Week 9	0.20 Units on a scale Standard Deviation 26.34	-6.33 Units on a scale Standard Deviation 26.62
Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by European Organization for the Research and Treatment of Cancer (EORTC) Quality-of-Life Questionnaire-Core 30 (QLQ-C30) Symptom Score Dyspnoea: Week 12	-0.91 Units on a scale Standard Deviation 27.57	-3.39 Units on a scale Standard Deviation 29.10
Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by European Organization for the Research and Treatment of Cancer (EORTC) Quality-of-Life Questionnaire-Core 30 (QLQ-C30) Symptom Score Dyspnoea: Week 15	-1.67 Units on a scale Standard Deviation 28.92	-2.44 Units on a scale Standard Deviation 28.73
Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by European Organization for the Research and Treatment of Cancer (EORTC) Quality-of-Life Questionnaire-Core 30 (QLQ-C30) Symptom Score Dyspnoea: Week 18	-2.12 Units on a scale Standard Deviation 24.85	-3.44 Units on a scale Standard Deviation 30.43
Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by European Organization for the Research and Treatment of Cancer (EORTC) Quality-of-Life Questionnaire-Core 30 (QLQ-C30) Symptom Score Dyspnoea: Week 21	-5.67 Units on a scale Standard Deviation 29.61	-2.89 Units on a scale Standard Deviation 31.83
Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by European Organization for the Research and Treatment of Cancer (EORTC) Quality-of-Life Questionnaire-Core 30 (QLQ-C30) Symptom Score Dyspnoea: Week 24	-2.75 Units on a scale Standard Deviation 28.74	-2.45 Units on a scale Standard Deviation 31.85
Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by European Organization for the Research and Treatment of Cancer (EORTC) Quality-of-Life Questionnaire-Core 30 (QLQ-C30) Symptom Score Dyspnoea: Week 27	-2.53 Units on a scale Standard Deviation 31.47	-1.32 Units on a scale Standard Deviation 27.13
Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by European Organization for the Research and Treatment of Cancer (EORTC) Quality-of-Life Questionnaire-Core 30 (QLQ-C30) Symptom Score Dyspnoea: Week 30	-1.25 Units on a scale Standard Deviation 32.45	-2.71 Units on a scale Standard Deviation 28.50
Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by European Organization for the Research and Treatment of Cancer (EORTC) Quality-of-Life Questionnaire-Core 30 (QLQ-C30) Symptom Score Dyspnoea: Week 33	-1.83 Units on a scale Standard Deviation 27.15	-3.74 Units on a scale Standard Deviation 30.14
Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by European Organization for the Research and Treatment of Cancer (EORTC) Quality-of-Life Questionnaire-Core 30 (QLQ-C30) Symptom Score Dyspnoea: Week 36	-3.83 Units on a scale Standard Deviation 30.49	-6.67 Units on a scale Standard Deviation 31.49
Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by European Organization for the Research and Treatment of Cancer (EORTC) Quality-of-Life Questionnaire-Core 30 (QLQ-C30) Symptom Score Dyspnoea: Week 39	-1.67 Units on a scale Standard Deviation 31.55	-8.42 Units on a scale Standard Deviation 29.16
Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by European Organization for the Research and Treatment of Cancer (EORTC) Quality-of-Life Questionnaire-Core 30 (QLQ-C30) Symptom Score Dyspnoea: Week 42	-3.27 Units on a scale Standard Deviation 28.48	-9.12 Units on a scale Standard Deviation 28.12
Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by European Organization for the Research and Treatment of Cancer (EORTC) Quality-of-Life Questionnaire-Core 30 (QLQ-C30) Symptom Score Dyspnoea: Week 45	-6.25 Units on a scale Standard Deviation 32.00	-2.11 Units on a scale Standard Deviation 30.82
Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by European Organization for the Research and Treatment of Cancer (EORTC) Quality-of-Life Questionnaire-Core 30 (QLQ-C30) Symptom Score Dyspnoea: Week 48	-5.13 Units on a scale Standard Deviation 32.03	-7.41 Units on a scale Standard Deviation 26.87
Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by European Organization for the Research and Treatment of Cancer (EORTC) Quality-of-Life Questionnaire-Core 30 (QLQ-C30) Symptom Score Dyspnoea: Week 51	-14.81 Units on a scale Standard Deviation 30.28	-2.92 Units on a scale Standard Deviation 26.09
Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by European Organization for the Research and Treatment of Cancer (EORTC) Quality-of-Life Questionnaire-Core 30 (QLQ-C30) Symptom Score Dyspnoea: Week 54	-9.68 Units on a scale Standard Deviation 35.69	-2.78 Units on a scale Standard Deviation 27.26
Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by European Organization for the Research and Treatment of Cancer (EORTC) Quality-of-Life Questionnaire-Core 30 (QLQ-C30) Symptom Score Dyspnoea: Week 57	-7.69 Units on a scale Standard Deviation 28.76	-5.63 Units on a scale Standard Deviation 28.72
Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by European Organization for the Research and Treatment of Cancer (EORTC) Quality-of-Life Questionnaire-Core 30 (QLQ-C30) Symptom Score Dyspnoea: Week 60	-11.11 Units on a scale Standard Deviation 25.57	0.00 Units on a scale Standard Deviation 25.43
Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by European Organization for the Research and Treatment of Cancer (EORTC) Quality-of-Life Questionnaire-Core 30 (QLQ-C30) Symptom Score Dyspnoea: Week 63	-7.69 Units on a scale Standard Deviation 14.62	-5.13 Units on a scale Standard Deviation 23.62
Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by European Organization for the Research and Treatment of Cancer (EORTC) Quality-of-Life Questionnaire-Core 30 (QLQ-C30) Symptom Score Dyspnoea: Week 66	-9.52 Units on a scale Standard Deviation 16.27	-1.80 Units on a scale Standard Deviation 24.78
Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by European Organization for the Research and Treatment of Cancer (EORTC) Quality-of-Life Questionnaire-Core 30 (QLQ-C30) Symptom Score Dyspnoea: Week 69	-16.67 Units on a scale Standard Deviation 18.26	-3.57 Units on a scale Standard Deviation 24.58
Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by European Organization for the Research and Treatment of Cancer (EORTC) Quality-of-Life Questionnaire-Core 30 (QLQ-C30) Symptom Score Dyspnoea: Week 72	-4.17 Units on a scale Standard Deviation 27.82	0.00 Units on a scale Standard Deviation 27.22
Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by European Organization for the Research and Treatment of Cancer (EORTC) Quality-of-Life Questionnaire-Core 30 (QLQ-C30) Symptom Score Dyspnoea: Week 75	-6.67 Units on a scale Standard Deviation 14.91	-5.80 Units on a scale Standard Deviation 19.21
Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by European Organization for the Research and Treatment of Cancer (EORTC) Quality-of-Life Questionnaire-Core 30 (QLQ-C30) Symptom Score Dyspnoea: Week 78	0.00 Units on a scale Standard Deviation 0.00	-4.76 Units on a scale Standard Deviation 25.68
Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by European Organization for the Research and Treatment of Cancer (EORTC) Quality-of-Life Questionnaire-Core 30 (QLQ-C30) Symptom Score Dyspnoea: Week 81	0.00 Units on a scale Standard Deviation 0.00	-11.11 Units on a scale Standard Deviation 23.57
Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by European Organization for the Research and Treatment of Cancer (EORTC) Quality-of-Life Questionnaire-Core 30 (QLQ-C30) Symptom Score Dyspnoea: Week 84	0.00 Units on a scale Standard Deviation 0.00	-4.17 Units on a scale Standard Deviation 21.36
Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by European Organization for the Research and Treatment of Cancer (EORTC) Quality-of-Life Questionnaire-Core 30 (QLQ-C30) Symptom Score Dyspnoea: Week 87	0.00 Units on a scale Standard Deviation NA Only 1 participant.	8.33 Units on a scale Standard Deviation 16.67
Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by European Organization for the Research and Treatment of Cancer (EORTC) Quality-of-Life Questionnaire-Core 30 (QLQ-C30) Symptom Score Dyspnoea: Week 90	0.00 Units on a scale Standard Deviation NA Only 1 participant.	0.00 Units on a scale Standard Deviation 0.00
Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by European Organization for the Research and Treatment of Cancer (EORTC) Quality-of-Life Questionnaire-Core 30 (QLQ-C30) Symptom Score Dyspnoea: Week 93	—	0.00 Units on a scale Standard Deviation NA Only 1 participant.
Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by European Organization for the Research and Treatment of Cancer (EORTC) Quality-of-Life Questionnaire-Core 30 (QLQ-C30) Symptom Score Dyspnoea: Survival Follow-Up Week 12	9.20 Units on a scale Standard Deviation 35.52	8.00 Units on a scale Standard Deviation 42.25
Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by European Organization for the Research and Treatment of Cancer (EORTC) Quality-of-Life Questionnaire-Core 30 (QLQ-C30) Symptom Score Dyspnoea: Survival Follow-Up Week 24	5.26 Units on a scale Standard Deviation 25.49	-14.29 Units on a scale Standard Deviation 17.82

SECONDARY outcome

Timeframe: Baseline up to 3 and 6 months after disease progression or loss of clinical benefit (up to approximately 25 months)

Population: ITT population with a non-missing baseline and at least a post-baseline PRO assessment (i.e., PRO evaluable population).

The EORTC QLQ-LC13 module incorporates one multiple item scale to assess dyspnea and a series of single items assessing pain, coughing, sore mouth, dysphagia, peripheral neuropathy, alopecia, and hemoptysis. The EORTC QLQ-LC13 is scored according to the EORTC scoring manual (Fayers et al. 2001). All EORTC scales and single-item measures are linearly transformed so that each score has a range of 0-100. A high score for a functional/global health status scale represents a high or healthy level of functioning/HRQoL (Health-Related Quality of Life); however, a high score for a symptom scale or item represents a high level of symptomatology or problems. A≥10-point change in the symptoms subscale score is perceived by patients as clinically significant (Osoba et al. 1998).

Outcome measures

Outcome measures
Measure	Arm B (Carboplatin or Cisplatin + Pemetrexed) n=230 Participants Participants received IV infusion of 500 mg/m\^2 pemetrexed on Day 1 q3w, and as per investigator's choice of either IV infusion of carboplatin on Day 1 q3w with a dose calculated using 'Calvert formula' to obtain AUC =6 mg/mL/min or IV infusion of 75 mg/m\^2 cisplatin q3w on Day 1 q3w, during induction dosing period for 4 or 6 cycles (Cycle length=21 days). Participants who did not experience disease progression during the induction phase began maintenance therapy. Participants will receive IV infusion of 500 mg/m\^2 of pemetrexed on Day 1 q3w until disease progression in the maintenance period.	Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed n=234 Participants Participants received intravenous (IV) infusion of 1200 milligrams (mg) of atezolizumab on Day 1 every 3 weeks (q3w), IV infusion of 500 milligrams per meter square (mg/m\^2) pemetrexed on Day 1 q3w, and as per investigator's choice either IV infusion of carboplatin on Day 1 q3w with a dose calculated using 'Calvert formula' to obtain area under concentration versus time (AUC) = 6 milligrams per milliliter per minute (mg/mL/min) or IV infusion of 75 mg/m\^2 cisplatin q3w on Day 1 q3w, during induction dosing period of 4 or 6 cycles (Cycle length=21 days). Participants who experienced clinical benefit during the induction phase began maintenance therapy. Participants will receive IV infusion of 1200 mg of atezolizumab and 500 mg/m\^2 of pemetrexed on Day 1 q3w until disease progression in the maintenance period.
Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by EORTC Quality-of-Life Lung Cancer Module (QLQ-LC13) Symptom Score Coughing: Week 3	-2.50 Units on a scale Standard Deviation 25.37	-3.41 Units on a scale Standard Deviation 26.90
Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by EORTC Quality-of-Life Lung Cancer Module (QLQ-LC13) Symptom Score Coughing: Week 6	-3.57 Units on a scale Standard Deviation 27.20	-9.82 Units on a scale Standard Deviation 26.50
Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by EORTC Quality-of-Life Lung Cancer Module (QLQ-LC13) Symptom Score Coughing: Week 9	-1.85 Units on a scale Standard Deviation 24.43	-8.29 Units on a scale Standard Deviation 31.37
Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by EORTC Quality-of-Life Lung Cancer Module (QLQ-LC13) Symptom Score Coughing: Week 12	-3.91 Units on a scale Standard Deviation 28.46	-10.71 Units on a scale Standard Deviation 31.66
Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by EORTC Quality-of-Life Lung Cancer Module (QLQ-LC13) Symptom Score Coughing: Week 15	-6.33 Units on a scale Standard Deviation 30.39	-11.53 Units on a scale Standard Deviation 29.05
Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by EORTC Quality-of-Life Lung Cancer Module (QLQ-LC13) Symptom Score Coughing: Week 18	-4.00 Units on a scale Standard Deviation 26.97	-11.63 Units on a scale Standard Deviation 27.92
Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by EORTC Quality-of-Life Lung Cancer Module (QLQ-LC13) Symptom Score Coughing: Week 21	-6.00 Units on a scale Standard Deviation 27.78	-10.50 Units on a scale Standard Deviation 30.76
Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by EORTC Quality-of-Life Lung Cancer Module (QLQ-LC13) Symptom Score Coughing: Week 24	-4.81 Units on a scale Standard Deviation 28.05	-10.03 Units on a scale Standard Deviation 33.08
Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by EORTC Quality-of-Life Lung Cancer Module (QLQ-LC13) Symptom Score Coughing: Week 27	-3.85 Units on a scale Standard Deviation 26.85	-11.65 Units on a scale Standard Deviation 34.40
Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by EORTC Quality-of-Life Lung Cancer Module (QLQ-LC13) Symptom Score Coughing: Week 30	0.42 Units on a scale Standard Deviation 29.76	-11.39 Units on a scale Standard Deviation 31.31
Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by EORTC Quality-of-Life Lung Cancer Module (QLQ-LC13) Symptom Score Coughing: Week 33	-0.46 Units on a scale Standard Deviation 26.53	-11.97 Units on a scale Standard Deviation 30.91
Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by EORTC Quality-of-Life Lung Cancer Module (QLQ-LC13) Symptom Score Coughing: Week 36	-6.11 Units on a scale Standard Deviation 31.59	-12.94 Units on a scale Standard Deviation 30.33
Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by EORTC Quality-of-Life Lung Cancer Module (QLQ-LC13) Symptom Score Coughing: Week 39	-5.00 Units on a scale Standard Deviation 30.58	-13.41 Units on a scale Standard Deviation 32.43
Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by EORTC Quality-of-Life Lung Cancer Module (QLQ-LC13) Symptom Score Coughing: Week 42	-8.97 Units on a scale Standard Deviation 27.31	-14.70 Units on a scale Standard Deviation 29.68
Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by EORTC Quality-of-Life Lung Cancer Module (QLQ-LC13) Symptom Score Coughing: Week 45	-13.19 Units on a scale Standard Deviation 28.13	-14.72 Units on a scale Standard Deviation 27.83
Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by EORTC Quality-of-Life Lung Cancer Module (QLQ-LC13) Symptom Score Coughing: Week 48	-7.69 Units on a scale Standard Deviation 31.96	-13.92 Units on a scale Standard Deviation 32.29
Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by EORTC Quality-of-Life Lung Cancer Module (QLQ-LC13) Symptom Score Coughing: Week 51	-17.59 Units on a scale Standard Deviation 25.80	-10.97 Units on a scale Standard Deviation 34.48
Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by EORTC Quality-of-Life Lung Cancer Module (QLQ-LC13) Symptom Score Coughing: Week 54	-17.20 Units on a scale Standard Deviation 27.04	-13.81 Units on a scale Standard Deviation 33.81
Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by EORTC Quality-of-Life Lung Cancer Module (QLQ-LC13) Symptom Score Coughing: Week 57	-11.54 Units on a scale Standard Deviation 22.98	-13.53 Units on a scale Standard Deviation 29.33
Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by EORTC Quality-of-Life Lung Cancer Module (QLQ-LC13) Symptom Score Coughing: Week 60	-14.04 Units on a scale Standard Deviation 27.92	-10.71 Units on a scale Standard Deviation 31.21
Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by EORTC Quality-of-Life Lung Cancer Module (QLQ-LC13) Symptom Score Coughing: Week 63	-10.26 Units on a scale Standard Deviation 21.01	-12.82 Units on a scale Standard Deviation 27.16
Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by EORTC Quality-of-Life Lung Cancer Module (QLQ-LC13) Symptom Score Coughing: Week 66	-9.52 Units on a scale Standard Deviation 25.20	-12.61 Units on a scale Standard Deviation 28.71
Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by EORTC Quality-of-Life Lung Cancer Module (QLQ-LC13) Symptom Score Coughing: Week 69	-11.11 Units on a scale Standard Deviation 27.22	-11.90 Units on a scale Standard Deviation 30.38
Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by EORTC Quality-of-Life Lung Cancer Module (QLQ-LC13) Symptom Score Coughing: Week 72	-8.33 Units on a scale Standard Deviation 23.57	-16.67 Units on a scale Standard Deviation 30.43
Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by EORTC Quality-of-Life Lung Cancer Module (QLQ-LC13) Symptom Score Coughing: Week 75	-13.33 Units on a scale Standard Deviation 18.26	-18.84 Units on a scale Standard Deviation 28.12
Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by EORTC Quality-of-Life Lung Cancer Module (QLQ-LC13) Symptom Score Coughing: Week 78	-16.67 Units on a scale Standard Deviation 23.57	-23.81 Units on a scale Standard Deviation 27.51
Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by EORTC Quality-of-Life Lung Cancer Module (QLQ-LC13) Symptom Score Coughing: Week 81	-16.67 Units on a scale Standard Deviation 23.57	-18.52 Units on a scale Standard Deviation 33.79
Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by EORTC Quality-of-Life Lung Cancer Module (QLQ-LC13) Symptom Score Coughing: Week 84	-33.33 Units on a scale Standard Deviation 0.00	-29.17 Units on a scale Standard Deviation 27.82
Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by EORTC Quality-of-Life Lung Cancer Module (QLQ-LC13) Symptom Score Coughing: Week 87	0.00 Units on a scale Standard Deviation NA Only 1 participant.	-25.00 Units on a scale Standard Deviation 31.91
Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by EORTC Quality-of-Life Lung Cancer Module (QLQ-LC13) Symptom Score Coughing: Week 90	-33.33 Units on a scale Standard Deviation NA Only 1 participant.	-16.67 Units on a scale Standard Deviation 23.57
Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by EORTC Quality-of-Life Lung Cancer Module (QLQ-LC13) Symptom Score Coughing: Week 93	—	0.00 Units on a scale Standard Deviation NA Only 1 participant.
Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by EORTC Quality-of-Life Lung Cancer Module (QLQ-LC13) Symptom Score Coughing: Time of First Pd	-6.01 Units on a scale Standard Deviation 30.13	-10.48 Units on a scale Standard Deviation 28.68
Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by EORTC Quality-of-Life Lung Cancer Module (QLQ-LC13) Symptom Score Coughing: Time of Last Tx Dose	-5.19 Units on a scale Standard Deviation 28.05	-8.13 Units on a scale Standard Deviation 28.78
Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by EORTC Quality-of-Life Lung Cancer Module (QLQ-LC13) Symptom Score Coughing: Survival Follow-Up Week 12	3.57 Units on a scale Standard Deviation 29.17	-6.94 Units on a scale Standard Deviation 34.02
Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by EORTC Quality-of-Life Lung Cancer Module (QLQ-LC13) Symptom Score Coughing: Survival Follow-Up Week 24	-8.77 Units on a scale Standard Deviation 24.45	-14.29 Units on a scale Standard Deviation 32.53
Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by EORTC Quality-of-Life Lung Cancer Module (QLQ-LC13) Symptom Score Dyspnoea: Week 3	0.21 Units on a scale Standard Deviation 18.69	-1.41 Units on a scale Standard Deviation 17.68
Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by EORTC Quality-of-Life Lung Cancer Module (QLQ-LC13) Symptom Score Dyspnoea: Week 6	0.12 Units on a scale Standard Deviation 17.13	-1.17 Units on a scale Standard Deviation 18.85
Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by EORTC Quality-of-Life Lung Cancer Module (QLQ-LC13) Symptom Score Dyspnoea: Week 9	0.89 Units on a scale Standard Deviation 20.68	-3.34 Units on a scale Standard Deviation 18.65
Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by EORTC Quality-of-Life Lung Cancer Module (QLQ-LC13) Symptom Score Dyspnoea: Week 12	1.15 Units on a scale Standard Deviation 21.82	-0.46 Units on a scale Standard Deviation 21.76
Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by EORTC Quality-of-Life Lung Cancer Module (QLQ-LC13) Symptom Score Dyspnoea: Week 15	0.00 Units on a scale Standard Deviation 21.30	-1.12 Units on a scale Standard Deviation 20.78
Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by EORTC Quality-of-Life Lung Cancer Module (QLQ-LC13) Symptom Score Dyspnoea: Week 18	-1.07 Units on a scale Standard Deviation 18.90	-3.88 Units on a scale Standard Deviation 21.92
Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by EORTC Quality-of-Life Lung Cancer Module (QLQ-LC13) Symptom Score Dyspnoea: Week 21	-3.56 Units on a scale Standard Deviation 22.77	-1.45 Units on a scale Standard Deviation 21.85
Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by EORTC Quality-of-Life Lung Cancer Module (QLQ-LC13) Symptom Score Dyspnoea: Week 24	-2.29 Units on a scale Standard Deviation 21.75	-0.42 Units on a scale Standard Deviation 23.82
Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by EORTC Quality-of-Life Lung Cancer Module (QLQ-LC13) Symptom Score Dyspnoea: Week 27	-0.71 Units on a scale Standard Deviation 22.32	-2.08 Units on a scale Standard Deviation 19.83
Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by EORTC Quality-of-Life Lung Cancer Module (QLQ-LC13) Symptom Score Dyspnoea: Week 30	1.25 Units on a scale Standard Deviation 22.57	-2.78 Units on a scale Standard Deviation 20.33
Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by EORTC Quality-of-Life Lung Cancer Module (QLQ-LC13) Symptom Score Dyspnoea: Week 33	0.77 Units on a scale Standard Deviation 21.45	-3.02 Units on a scale Standard Deviation 22.82
Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by EORTC Quality-of-Life Lung Cancer Module (QLQ-LC13) Symptom Score Dyspnoea: Week 36	-1.11 Units on a scale Standard Deviation 20.93	-2.91 Units on a scale Standard Deviation 23.70
Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by EORTC Quality-of-Life Lung Cancer Module (QLQ-LC13) Symptom Score Dyspnoea: Week 39	1.30 Units on a scale Standard Deviation 26.91	-4.95 Units on a scale Standard Deviation 22.31
Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by EORTC Quality-of-Life Lung Cancer Module (QLQ-LC13) Symptom Score Dyspnoea: Week 42	-0.43 Units on a scale Standard Deviation 22.65	-6.33 Units on a scale Standard Deviation 18.64
Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by EORTC Quality-of-Life Lung Cancer Module (QLQ-LC13) Symptom Score Dyspnoea: Week 45	-2.08 Units on a scale Standard Deviation 26.60	-3.61 Units on a scale Standard Deviation 21.36
Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by EORTC Quality-of-Life Lung Cancer Module (QLQ-LC13) Symptom Score Dyspnoea: Week 48	-4.56 Units on a scale Standard Deviation 24.94	-5.34 Units on a scale Standard Deviation 21.49
Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by EORTC Quality-of-Life Lung Cancer Module (QLQ-LC13) Symptom Score Dyspnoea: Week 51	-9.88 Units on a scale Standard Deviation 21.87	-1.69 Units on a scale Standard Deviation 18.41
Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by EORTC Quality-of-Life Lung Cancer Module (QLQ-LC13) Symptom Score Dyspnoea: Week 54	-6.45 Units on a scale Standard Deviation 24.47	-1.90 Units on a scale Standard Deviation 19.10
Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by EORTC Quality-of-Life Lung Cancer Module (QLQ-LC13) Symptom Score Dyspnoea: Week 57	-2.99 Units on a scale Standard Deviation 23.42	-4.99 Units on a scale Standard Deviation 22.99
Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by EORTC Quality-of-Life Lung Cancer Module (QLQ-LC13) Symptom Score Dyspnoea: Week 60	-11.11 Units on a scale Standard Deviation 23.42	-0.40 Units on a scale Standard Deviation 22.32
Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by EORTC Quality-of-Life Lung Cancer Module (QLQ-LC13) Symptom Score Dyspnoea: Week 63	-6.84 Units on a scale Standard Deviation 15.41	-6.55 Units on a scale Standard Deviation 23.04
Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by EORTC Quality-of-Life Lung Cancer Module (QLQ-LC13) Symptom Score Dyspnoea: Week 66	-9.52 Units on a scale Standard Deviation 16.27	-4.50 Units on a scale Standard Deviation 21.98
Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by EORTC Quality-of-Life Lung Cancer Module (QLQ-LC13) Symptom Score Dyspnoea: Week 69	-16.67 Units on a scale Standard Deviation 21.94	-4.76 Units on a scale Standard Deviation 23.12
Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by EORTC Quality-of-Life Lung Cancer Module (QLQ-LC13) Symptom Score Dyspnoea: Week 72	-5.56 Units on a scale Standard Deviation 19.70	-1.52 Units on a scale Standard Deviation 24.56
Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by EORTC Quality-of-Life Lung Cancer Module (QLQ-LC13) Symptom Score Dyspnoea: Week 75	-6.67 Units on a scale Standard Deviation 14.91	-6.76 Units on a scale Standard Deviation 17.64
Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by EORTC Quality-of-Life Lung Cancer Module (QLQ-LC13) Symptom Score Dyspnoea: Week 78	0.00 Units on a scale Standard Deviation 0.00	-3.17 Units on a scale Standard Deviation 21.09
Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by EORTC Quality-of-Life Lung Cancer Module (QLQ-LC13) Symptom Score Dyspnoea: Week 81	11.11 Units on a scale Standard Deviation 15.71	-9.88 Units on a scale Standard Deviation 22.53
Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by EORTC Quality-of-Life Lung Cancer Module (QLQ-LC13) Symptom Score Dyspnoea: Week 84	0.00 Units on a scale Standard Deviation 0.00	-6.94 Units on a scale Standard Deviation 22.17
Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by EORTC Quality-of-Life Lung Cancer Module (QLQ-LC13) Symptom Score Dyspnoea: Week 87	0.00 Units on a scale	-2.78 Units on a scale Standard Deviation 18.98
Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by EORTC Quality-of-Life Lung Cancer Module (QLQ-LC13) Symptom Score Dyspnoea: Week 90	0.00 Units on a scale	5.56 Units on a scale Standard Deviation 23.57
Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by EORTC Quality-of-Life Lung Cancer Module (QLQ-LC13) Symptom Score Dyspnoea: Week 93	—	22.22 Units on a scale Standard Deviation NA Only 1 participant.
Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by EORTC Quality-of-Life Lung Cancer Module (QLQ-LC13) Symptom Score Dyspnoea: Time of First PD	2.37 Units on a scale Standard Deviation 22.05	-0.16 Units on a scale Standard Deviation 24.48
Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by EORTC Quality-of-Life Lung Cancer Module (QLQ-LC13) Symptom Score Dyspnoea: Time of Last Tx Dose	3.96 Units on a scale Standard Deviation 22.74	0.44 Units on a scale Standard Deviation 21.83
Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by EORTC Quality-of-Life Lung Cancer Module (QLQ-LC13) Symptom Score Dyspnoea: Survival Follow-Up Week 12	9.92 Units on a scale Standard Deviation 25.90	13.43 Units on a scale Standard Deviation 33.73
Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by EORTC Quality-of-Life Lung Cancer Module (QLQ-LC13) Symptom Score Dyspnoea: Survival Follow-Up Week 24	4.68 Units on a scale Standard Deviation 17.50	4.76 Units on a scale Standard Deviation 23.00
Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by EORTC Quality-of-Life Lung Cancer Module (QLQ-LC13) Symptom Score Pain In Chest: Week 3	-1.25 Units on a scale Standard Deviation 21.19	0.81 Units on a scale Standard Deviation 23.67
Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by EORTC Quality-of-Life Lung Cancer Module (QLQ-LC13) Symptom Score Pain In Chest: Week 6	0.71 Units on a scale Standard Deviation 25.15	-6.32 Units on a scale Standard Deviation 24.39
Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by EORTC Quality-of-Life Lung Cancer Module (QLQ-LC13) Symptom Score Pain In Chest: Week 9	0.82 Units on a scale Standard Deviation 24.63	-4.24 Units on a scale Standard Deviation 25.57
Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by EORTC Quality-of-Life Lung Cancer Module (QLQ-LC13) Symptom Score Pain In Chest: Week 12	-2.07 Units on a scale Standard Deviation 24.60	-0.60 Units on a scale Standard Deviation 27.65
Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by EORTC Quality-of-Life Lung Cancer Module (QLQ-LC13) Symptom Score Pain In Chest: Week 15	-1.46 Units on a scale Standard Deviation 24.88	-3.56 Units on a scale Standard Deviation 25.60
Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by EORTC Quality-of-Life Lung Cancer Module (QLQ-LC13) Symptom Score Pain In Chest: Week 18	-3.47 Units on a scale Standard Deviation 26.38	-3.36 Units on a scale Standard Deviation 26.77
Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by EORTC Quality-of-Life Lung Cancer Module (QLQ-LC13) Symptom Score Pain In Chest: Week 21	-3.33 Units on a scale Standard Deviation 26.17	-2.74 Units on a scale Standard Deviation 25.22
Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by EORTC Quality-of-Life Lung Cancer Module (QLQ-LC13) Symptom Score Pain In Chest: Week 24	-2.41 Units on a scale Standard Deviation 26.89	-4.76 Units on a scale Standard Deviation 29.05
Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by EORTC Quality-of-Life Lung Cancer Module (QLQ-LC13) Symptom Score Pain In Chest: Week 27	-5.13 Units on a scale Standard Deviation 29.95	-2.71 Units on a scale Standard Deviation 22.82
Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by EORTC Quality-of-Life Lung Cancer Module (QLQ-LC13) Symptom Score Pain In Chest: Week 30	-4.17 Units on a scale Standard Deviation 29.71	-3.06 Units on a scale Standard Deviation 27.33
Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by EORTC Quality-of-Life Lung Cancer Module (QLQ-LC13) Symptom Score Pain In Chest: Week 33	-0.46 Units on a scale Standard Deviation 29.86	-3.88 Units on a scale Standard Deviation 28.12
Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by EORTC Quality-of-Life Lung Cancer Module (QLQ-LC13) Symptom Score Pain In Chest: Week 36	-1.67 Units on a scale Standard Deviation 31.55	-2.91 Units on a scale Standard Deviation 27.26
Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by EORTC Quality-of-Life Lung Cancer Module (QLQ-LC13) Symptom Score Pain In Chest: Week 39	-3.89 Units on a scale Standard Deviation 30.12	-3.99 Units on a scale Standard Deviation 27.44
Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by EORTC Quality-of-Life Lung Cancer Module (QLQ-LC13) Symptom Score Pain In Chest: Week 42	-7.69 Units on a scale Standard Deviation 29.24	-7.17 Units on a scale Standard Deviation 26.40
Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by EORTC Quality-of-Life Lung Cancer Module (QLQ-LC13) Symptom Score Pain In Chest: Week 45	-6.25 Units on a scale Standard Deviation 29.70	-5.63 Units on a scale Standard Deviation 25.02
Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by EORTC Quality-of-Life Lung Cancer Module (QLQ-LC13) Symptom Score Pain In Chest: Week 48	-7.69 Units on a scale Standard Deviation 29.08	-4.64 Units on a scale Standard Deviation 24.88
Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by EORTC Quality-of-Life Lung Cancer Module (QLQ-LC13) Symptom Score Pain In Chest: Week 51	-11.11 Units on a scale Standard Deviation 28.73	-5.49 Units on a scale Standard Deviation 24.13
Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by EORTC Quality-of-Life Lung Cancer Module (QLQ-LC13) Symptom Score Pain In Chest: Week 54	-7.53 Units on a scale Standard Deviation 29.45	-4.29 Units on a scale Standard Deviation 25.33
Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by EORTC Quality-of-Life Lung Cancer Module (QLQ-LC13) Symptom Score Pain In Chest: Week 57	-1.28 Units on a scale Standard Deviation 31.95	-5.80 Units on a scale Standard Deviation 26.17
Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by EORTC Quality-of-Life Lung Cancer Module (QLQ-LC13) Symptom Score Pain In Chest: Week 60	0.00 Units on a scale Standard Deviation 22.22	-3.57 Units on a scale Standard Deviation 27.47
Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by EORTC Quality-of-Life Lung Cancer Module (QLQ-LC13) Symptom Score Pain In Chest: Week 63	-5.13 Units on a scale Standard Deviation 18.49	-6.84 Units on a scale Standard Deviation 25.57
Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by EORTC Quality-of-Life Lung Cancer Module (QLQ-LC13) Symptom Score Pain In Chest: Week 66	-4.76 Units on a scale Standard Deviation 23.00	-4.50 Units on a scale Standard Deviation 27.40
Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by EORTC Quality-of-Life Lung Cancer Module (QLQ-LC13) Symptom Score Pain In Chest: Week 69	-16.67 Units on a scale Standard Deviation 18.26	-5.95 Units on a scale Standard Deviation 31.50
Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by EORTC Quality-of-Life Lung Cancer Module (QLQ-LC13) Symptom Score Pain In Chest: Week 72	-8.33 Units on a scale Standard Deviation 23.57	-4.55 Units on a scale Standard Deviation 23.67
Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by EORTC Quality-of-Life Lung Cancer Module (QLQ-LC13) Symptom Score Pain In Chest: Week 75	-6.67 Units on a scale Standard Deviation 14.91	0.00 Units on a scale Standard Deviation 20.10
Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by EORTC Quality-of-Life Lung Cancer Module (QLQ-LC13) Symptom Score Pain In Chest: Week 78	0.00 Units on a scale Standard Deviation 0.00	0.00 Units on a scale Standard Deviation 26.15
Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by EORTC Quality-of-Life Lung Cancer Module (QLQ-LC13) Symptom Score Pain In Chest: Week 81	0.00 Units on a scale Standard Deviation 47.14	7.41 Units on a scale Standard Deviation 14.70
Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by EORTC Quality-of-Life Lung Cancer Module (QLQ-LC13) Symptom Score Pain In Chest: Week 84	0.00 Units on a scale Standard Deviation 0.00	4.17 Units on a scale Standard Deviation 21.36
Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by EORTC Quality-of-Life Lung Cancer Module (QLQ-LC13) Symptom Score Pain In Chest: Week 87	-33.33 Units on a scale Standard Deviation NA Only 1 participant.	8.33 Units on a scale Standard Deviation 16.67
Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by EORTC Quality-of-Life Lung Cancer Module (QLQ-LC13) Symptom Score Pain In Chest: Week 90	-33.33 Units on a scale Standard Deviation NA Only 1 participant.	0.00 Units on a scale Standard Deviation 0.00
Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by EORTC Quality-of-Life Lung Cancer Module (QLQ-LC13) Symptom Score Pain In Chest: Week 93	—	0.00 Units on a scale
Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by EORTC Quality-of-Life Lung Cancer Module (QLQ-LC13) Symptom Score Pain In Chest: Time of First Pd	6.56 Units on a scale Standard Deviation 22.62	-3.81 Units on a scale Standard Deviation 29.24
Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by EORTC Quality-of-Life Lung Cancer Module (QLQ-LC13) Symptom Score Pain In Chest: Time of Last Tx Dose	1.34 Units on a scale Standard Deviation 25.26	-0.83 Units on a scale Standard Deviation 26.96
Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by EORTC Quality-of-Life Lung Cancer Module (QLQ-LC13) Symptom Score Pain In Chest: Survival Follow-Up Week 12	5.95 Units on a scale Standard Deviation 36.35	-2.78 Units on a scale Standard Deviation 32.48
Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by EORTC Quality-of-Life Lung Cancer Module (QLQ-LC13) Symptom Score Pain In Chest: Survival Follow-Up Week 24	1.75 Units on a scale Standard Deviation 17.48	-4.76 Units on a scale Standard Deviation 29.99
Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by EORTC Quality-of-Life Lung Cancer Module (QLQ-LC13) Symptom Score Pain In Arm Or Shoulder: Week 3	-4.69 Units on a scale Standard Deviation 25.26	-2.60 Units on a scale Standard Deviation 24.78
Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by EORTC Quality-of-Life Lung Cancer Module (QLQ-LC13) Symptom Score Pain In Arm Or Shoulder: Week 6	-4.46 Units on a scale Standard Deviation 23.14	-5.44 Units on a scale Standard Deviation 25.19
Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by EORTC Quality-of-Life Lung Cancer Module (QLQ-LC13) Symptom Score Pain In Arm Or Shoulder: Week 9	-2.88 Units on a scale Standard Deviation 25.85	-8.09 Units on a scale Standard Deviation 28.73
Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by EORTC Quality-of-Life Lung Cancer Module (QLQ-LC13) Symptom Score Pain In Arm Or Shoulder: Week 12	-6.90 Units on a scale Standard Deviation 23.54	-4.37 Units on a scale Standard Deviation 27.19
Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by EORTC Quality-of-Life Lung Cancer Module (QLQ-LC13) Symptom Score Pain In Arm Or Shoulder: Week 15	-3.89 Units on a scale Standard Deviation 23.24	-7.34 Units on a scale Standard Deviation 30.15
Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by EORTC Quality-of-Life Lung Cancer Module (QLQ-LC13) Symptom Score Pain In Arm Or Shoulder: Week 18	-5.07 Units on a scale Standard Deviation 25.77	-6.26 Units on a scale Standard Deviation 29.09
Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by EORTC Quality-of-Life Lung Cancer Module (QLQ-LC13) Symptom Score Pain In Arm Or Shoulder: Week 21	-6.00 Units on a scale Standard Deviation 21.91	-1.83 Units on a scale Standard Deviation 28.71
Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by EORTC Quality-of-Life Lung Cancer Module (QLQ-LC13) Symptom Score Pain In Arm Or Shoulder: Week 24	-2.41 Units on a scale Standard Deviation 28.16	-5.26 Units on a scale Standard Deviation 30.11
Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by EORTC Quality-of-Life Lung Cancer Module (QLQ-LC13) Symptom Score Pain In Arm Or Shoulder: Week 27	-5.56 Units on a scale Standard Deviation 28.13	-3.79 Units on a scale Standard Deviation 26.72
Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by EORTC Quality-of-Life Lung Cancer Module (QLQ-LC13) Symptom Score Pain In Arm Or Shoulder: Week 30	1.25 Units on a scale Standard Deviation 27.27	-3.33 Units on a scale Standard Deviation 29.12
Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by EORTC Quality-of-Life Lung Cancer Module (QLQ-LC13) Symptom Score Pain In Arm Or Shoulder: Week 33	-5.56 Units on a scale Standard Deviation 25.02	-1.94 Units on a scale Standard Deviation 27.54
Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by EORTC Quality-of-Life Lung Cancer Module (QLQ-LC13) Symptom Score Pain In Arm Or Shoulder: Week 36	-1.67 Units on a scale Standard Deviation 30.33	-3.24 Units on a scale Standard Deviation 31.49
Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by EORTC Quality-of-Life Lung Cancer Module (QLQ-LC13) Symptom Score Pain In Arm Or Shoulder: Week 39	-5.00 Units on a scale Standard Deviation 30.58	-3.99 Units on a scale Standard Deviation 30.80
Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by EORTC Quality-of-Life Lung Cancer Module (QLQ-LC13) Symptom Score Pain In Arm Or Shoulder: Week 42	0.00 Units on a scale Standard Deviation 28.77	-8.60 Units on a scale Standard Deviation 25.49
Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by EORTC Quality-of-Life Lung Cancer Module (QLQ-LC13) Symptom Score Pain In Arm Or Shoulder: Week 45	-0.69 Units on a scale Standard Deviation 27.06	-6.06 Units on a scale Standard Deviation 28.47
Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by EORTC Quality-of-Life Lung Cancer Module (QLQ-LC13) Symptom Score Pain In Arm Or Shoulder: Week 48	-1.71 Units on a scale Standard Deviation 27.52	-4.22 Units on a scale Standard Deviation 29.89
Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by EORTC Quality-of-Life Lung Cancer Module (QLQ-LC13) Symptom Score Pain In Arm Or Shoulder: Week 51	-2.78 Units on a scale Standard Deviation 25.67	-3.38 Units on a scale Standard Deviation 27.53
Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by EORTC Quality-of-Life Lung Cancer Module (QLQ-LC13) Symptom Score Pain In Arm Or Shoulder: Week 54	-1.08 Units on a scale Standard Deviation 21.92	-6.19 Units on a scale Standard Deviation 25.56
Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by EORTC Quality-of-Life Lung Cancer Module (QLQ-LC13) Symptom Score Pain In Arm Or Shoulder: Week 57	-1.28 Units on a scale Standard Deviation 22.07	-2.90 Units on a scale Standard Deviation 26.65
Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by EORTC Quality-of-Life Lung Cancer Module (QLQ-LC13) Symptom Score Pain In Arm Or Shoulder: Week 60	-5.26 Units on a scale Standard Deviation 20.07	-4.17 Units on a scale Standard Deviation 27.75
Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by EORTC Quality-of-Life Lung Cancer Module (QLQ-LC13) Symptom Score Pain In Arm Or Shoulder: Week 63	-5.13 Units on a scale Standard Deviation 18.49	-3.42 Units on a scale Standard Deviation 27.35
Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by EORTC Quality-of-Life Lung Cancer Module (QLQ-LC13) Symptom Score Pain In Arm Or Shoulder: Week 66	4.76 Units on a scale Standard Deviation 12.60	-1.80 Units on a scale Standard Deviation 31.37
Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by EORTC Quality-of-Life Lung Cancer Module (QLQ-LC13) Symptom Score Pain In Arm Or Shoulder: Week 69	0.00 Units on a scale Standard Deviation 0.00	-7.14 Units on a scale Standard Deviation 22.87
Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by EORTC Quality-of-Life Lung Cancer Module (QLQ-LC13) Symptom Score Pain In Arm Or Shoulder: Week 72	-8.33 Units on a scale Standard Deviation 15.43	-7.58 Units on a scale Standard Deviation 27.08
Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by EORTC Quality-of-Life Lung Cancer Module (QLQ-LC13) Symptom Score Pain In Arm Or Shoulder: Week 75	-6.67 Units on a scale Standard Deviation 14.91	-8.70 Units on a scale Standard Deviation 25.06
Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by EORTC Quality-of-Life Lung Cancer Module (QLQ-LC13) Symptom Score Pain In Arm Or Shoulder: Week 78	0.00 Units on a scale Standard Deviation 0.00	-2.38 Units on a scale Standard Deviation 24.33
Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by EORTC Quality-of-Life Lung Cancer Module (QLQ-LC13) Symptom Score Pain In Arm Or Shoulder: Week 81	0.00 Units on a scale Standard Deviation 0.00	3.70 Units on a scale Standard Deviation 11.11
Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by EORTC Quality-of-Life Lung Cancer Module (QLQ-LC13) Symptom Score Pain In Arm Or Shoulder: Week 84	0.00 Units on a scale Standard Deviation 0.00	4.17 Units on a scale Standard Deviation 21.36
Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by EORTC Quality-of-Life Lung Cancer Module (QLQ-LC13) Symptom Score Pain In Arm Or Shoulder: Week 87	0.00 Units on a scale Standard Deviation NA Only 1 participant.	-16.67 Units on a scale Standard Deviation 33.33
Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by EORTC Quality-of-Life Lung Cancer Module (QLQ-LC13) Symptom Score Pain In Arm Or Shoulder: Week 90	0.00 Units on a scale Standard Deviation NA Only 1 participant.	0.00 Units on a scale Standard Deviation 0.00
Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by EORTC Quality-of-Life Lung Cancer Module (QLQ-LC13) Symptom Score Pain In Arm Or Shoulder: Week 93	—	0.00 Units on a scale Standard Deviation NA Only 1 participant.
Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by EORTC Quality-of-Life Lung Cancer Module (QLQ-LC13) Symptom Score Pain In Arm Or Shoulder: Time of First Pd	2.19 Units on a scale Standard Deviation 28.46	1.90 Units on a scale Standard Deviation 25.94
Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by EORTC Quality-of-Life Lung Cancer Module (QLQ-LC13) Symptom Score Pain In Arm Or Shoulder: Time of Last Tx Dose	-0.50 Units on a scale Standard Deviation 27.11	0.33 Units on a scale Standard Deviation 30.55
Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by EORTC Quality-of-Life Lung Cancer Module (QLQ-LC13) Symptom Score Pain In Arm Or Shoulder:Survival Follow-Up Week 12	13.10 Units on a scale Standard Deviation 30.55	5.56 Units on a scale Standard Deviation 40.13
Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by EORTC Quality-of-Life Lung Cancer Module (QLQ-LC13) Symptom Score Pain In Arm Or Shoulder:Survival Follow-Up Week 24	1.75 Units on a scale Standard Deviation 28.27	0.00 Units on a scale Standard Deviation 0.00

SECONDARY outcome

Timeframe: Baseline up to 3 and 6 months after disease progression or loss of clinical benefit (up to approximately 25 months)

Population: ITT population with a non-missing baseline and at least a post-baseline PRO assessment (i.e., PRO evaluable population).

Change from baseline per SILC scale will be analyzed for each lung cancer symptoms scores. SILC questionnaire comprises 3 individual symptoms \& are scored at individual symptom level, thus have a dyspnea score, chest pain score, \& cough score. There are a total of 9 questions in SILC questionnaire, each question has a minimum value of 0 \& maximum value of 4. Each individual symptom score is calculated as average of responses for symptom items. 'Chest pain' score is mean of question 1 \& 2, 'Cough' score is mean of question 3 \& 4 and 'Dyspnea' score is mean of question 5 to 9 in SILC questionnaire. An increase in score is suggestive of a worsening in symptomology. A score change of ≥0.3 points for dyspnea \& cough symptom scores is considered to be clinically significant; whereas a score change of≥0.5 points for chest pain score is considered to be clinically significant.

Outcome measures

Outcome measures
Measure	Arm B (Carboplatin or Cisplatin + Pemetrexed) n=176 Participants Participants received IV infusion of 500 mg/m\^2 pemetrexed on Day 1 q3w, and as per investigator's choice of either IV infusion of carboplatin on Day 1 q3w with a dose calculated using 'Calvert formula' to obtain AUC =6 mg/mL/min or IV infusion of 75 mg/m\^2 cisplatin q3w on Day 1 q3w, during induction dosing period for 4 or 6 cycles (Cycle length=21 days). Participants who did not experience disease progression during the induction phase began maintenance therapy. Participants will receive IV infusion of 500 mg/m\^2 of pemetrexed on Day 1 q3w until disease progression in the maintenance period.	Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed n=200 Participants Participants received intravenous (IV) infusion of 1200 milligrams (mg) of atezolizumab on Day 1 every 3 weeks (q3w), IV infusion of 500 milligrams per meter square (mg/m\^2) pemetrexed on Day 1 q3w, and as per investigator's choice either IV infusion of carboplatin on Day 1 q3w with a dose calculated using 'Calvert formula' to obtain area under concentration versus time (AUC) = 6 milligrams per milliliter per minute (mg/mL/min) or IV infusion of 75 mg/m\^2 cisplatin q3w on Day 1 q3w, during induction dosing period of 4 or 6 cycles (Cycle length=21 days). Participants who experienced clinical benefit during the induction phase began maintenance therapy. Participants will receive IV infusion of 1200 mg of atezolizumab and 500 mg/m\^2 of pemetrexed on Day 1 q3w until disease progression in the maintenance period.
Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score Cough: Week 91	0.00 Units on a scale	-0.50 Units on a scale Standard Deviation 0.00
Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score Chest Pain: Week 45	-0.20 Units on a scale Standard Deviation 1.24	0.03 Units on a scale Standard Deviation 0.95
Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score Chest Pain: Week 46	-0.06 Units on a scale Standard Deviation 1.18	0.08 Units on a scale Standard Deviation 0.99
Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score Chest Pain: Week 47	0.02 Units on a scale Standard Deviation 1.09	0.09 Units on a scale Standard Deviation 0.91
Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score Chest Pain: Week 48	0.02 Units on a scale Standard Deviation 1.27	0.05 Units on a scale Standard Deviation 1.00
Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score Chest Pain: Week 49	-0.09 Units on a scale Standard Deviation 1.07	0.03 Units on a scale Standard Deviation 0.90
Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score Chest Pain: Week 50	-0.13 Units on a scale Standard Deviation 0.99	0.00 Units on a scale Standard Deviation 1.03
Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score Chest Pain: Week 51	-0.02 Units on a scale Standard Deviation 0.77	0.12 Units on a scale Standard Deviation 0.94
Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score Chest Pain: Week 52	0.14 Units on a scale Standard Deviation 1.06	0.00 Units on a scale Standard Deviation 1.11
Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score Chest Pain: Week 53	0.13 Units on a scale Standard Deviation 1.35	-0.01 Units on a scale Standard Deviation 1.06
Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score Chest Pain: Week 54	0.11 Units on a scale Standard Deviation 1.16	-0.08 Units on a scale Standard Deviation 1.10
Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score Chest Pain: Week 55	0.12 Units on a scale Standard Deviation 1.38	0.03 Units on a scale Standard Deviation 1.14
Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score Chest Pain: Week 56	0.13 Units on a scale Standard Deviation 1.46	0.04 Units on a scale Standard Deviation 1.18
Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score Chest Pain: Week 57	0.12 Units on a scale Standard Deviation 1.21	-0.01 Units on a scale Standard Deviation 1.15
Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score Chest Pain: Week 58	0.27 Units on a scale Standard Deviation 0.98	-0.12 Units on a scale Standard Deviation 1.10
Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score Chest Pain: Week 59	0.23 Units on a scale Standard Deviation 0.73	-0.23 Units on a scale Standard Deviation 1.01
Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score Chest Pain: Week 60	0.14 Units on a scale Standard Deviation 0.67	-0.15 Units on a scale Standard Deviation 1.17
Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score Chest Pain: Week 61	0.23 Units on a scale Standard Deviation 0.83	0.00 Units on a scale Standard Deviation 1.06
Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score Chest Pain: Week 62	0.46 Units on a scale Standard Deviation 0.72	-0.04 Units on a scale Standard Deviation 1.08
Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score Chest Pain: Week 63	0.25 Units on a scale Standard Deviation 0.75	-0.06 Units on a scale Standard Deviation 1.09
Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score Chest Pain: Week 64	0.15 Units on a scale Standard Deviation 0.78	0.09 Units on a scale Standard Deviation 0.95
Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score Dyspnoea: Week 17	0.35 Units on a scale Standard Deviation 1.04	0.15 Units on a scale Standard Deviation 1.00
Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score Dyspnoea: Week 18	0.35 Units on a scale Standard Deviation 0.99	0.22 Units on a scale Standard Deviation 0.99
Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score Dyspnoea: Week 19	0.30 Units on a scale Standard Deviation 1.02	0.22 Units on a scale Standard Deviation 0.97
Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score Dyspnoea: Week 20	0.30 Units on a scale Standard Deviation 1.09	0.27 Units on a scale Standard Deviation 1.06
Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score Dyspnoea: Week 21	0.22 Units on a scale Standard Deviation 1.03	0.22 Units on a scale Standard Deviation 1.05
Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score Dyspnoea: Week 22	0.16 Units on a scale Standard Deviation 1.10	0.28 Units on a scale Standard Deviation 1.03
Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score Dyspnoea: Week 23	0.24 Units on a scale Standard Deviation 1.05	0.22 Units on a scale Standard Deviation 1.03
Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score Dyspnoea: Week 24	0.30 Units on a scale Standard Deviation 0.98	0.24 Units on a scale Standard Deviation 0.99
Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score Dyspnoea: Week 25	0.50 Units on a scale Standard Deviation 1.05	0.28 Units on a scale Standard Deviation 0.99
Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score Dyspnoea: Week 26	0.30 Units on a scale Standard Deviation 1.05	0.24 Units on a scale Standard Deviation 1.04
Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score Dyspnoea: Week 27	0.43 Units on a scale Standard Deviation 1.17	0.24 Units on a scale Standard Deviation 1.06
Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score Dyspnoea: Week 28	0.46 Units on a scale Standard Deviation 1.02	0.25 Units on a scale Standard Deviation 0.97
Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score Dyspnoea: Week 29	0.43 Units on a scale Standard Deviation 1.06	0.20 Units on a scale Standard Deviation 1.01
Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score Dyspnoea: Week 30	0.45 Units on a scale Standard Deviation 1.08	0.21 Units on a scale Standard Deviation 0.99
Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score Dyspnoea: Week 31	0.35 Units on a scale Standard Deviation 1.03	0.15 Units on a scale Standard Deviation 0.99
Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score Dyspnoea: Week 32	0.48 Units on a scale Standard Deviation 1.03	0.16 Units on a scale Standard Deviation 1.01
Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score Dyspnoea: Week 33	0.36 Units on a scale Standard Deviation 0.96	0.17 Units on a scale Standard Deviation 0.95
Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score Dyspnoea: Week 34	0.47 Units on a scale Standard Deviation 1.15	0.24 Units on a scale Standard Deviation 1.04
Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score Dyspnoea: Week 35	0.42 Units on a scale Standard Deviation 1.00	0.23 Units on a scale Standard Deviation 1.03
Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score Dyspnoea: Week 36	0.59 Units on a scale Standard Deviation 1.06	0.22 Units on a scale Standard Deviation 1.02
Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score Dyspnoea: Week 37	0.53 Units on a scale Standard Deviation 1.17	0.24 Units on a scale Standard Deviation 1.03
Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score Dyspnoea: Week 38	0.59 Units on a scale Standard Deviation 1.06	0.22 Units on a scale Standard Deviation 1.07
Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score Dyspnoea: Week 39	0.65 Units on a scale Standard Deviation 1.04	0.19 Units on a scale Standard Deviation 1.01
Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score Dyspnoea: Week 40	0.62 Units on a scale Standard Deviation 1.02	0.19 Units on a scale Standard Deviation 0.95
Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score Dyspnoea: Week 41	0.63 Units on a scale Standard Deviation 1.01	0.16 Units on a scale Standard Deviation 0.95
Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score Dyspnoea: Week 42	0.50 Units on a scale Standard Deviation 1.01	0.17 Units on a scale Standard Deviation 0.92
Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score Chest Pain: Week 65	0.11 Units on a scale Standard Deviation 0.82	-0.03 Units on a scale Standard Deviation 0.99
Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score Chest Pain: Week 66	0.42 Units on a scale Standard Deviation 0.92	0.13 Units on a scale Standard Deviation 1.05
Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score Chest Pain: Week 67	0.36 Units on a scale Standard Deviation 0.85	0.02 Units on a scale Standard Deviation 1.00
Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score Chest Pain: Week 68	0.33 Units on a scale Standard Deviation 0.88	0.12 Units on a scale Standard Deviation 1.18
Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score Chest Pain: Week 69	0.07 Units on a scale Standard Deviation 0.93	-0.05 Units on a scale Standard Deviation 1.10
Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score Chest Pain: Week 70	0.25 Units on a scale Standard Deviation 0.88	0.03 Units on a scale Standard Deviation 1.11
Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score Chest Pain: Week 71	0.30 Units on a scale Standard Deviation 0.97	0.04 Units on a scale Standard Deviation 1.09
Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score Chest Pain: Week 72	-0.13 Units on a scale Standard Deviation 0.25	-0.22 Units on a scale Standard Deviation 0.94
Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score Chest Pain: Week 73	0.13 Units on a scale Standard Deviation 1.31	-0.10 Units on a scale Standard Deviation 1.01
Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score Chest Pain: Week 74	0.38 Units on a scale Standard Deviation 1.11	-0.02 Units on a scale Standard Deviation 1.14
Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score Chest Pain: Week 75	0.38 Units on a scale Standard Deviation 1.11	-0.07 Units on a scale Standard Deviation 1.14
Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score Chest Pain: Week 76	0.00 Units on a scale Standard Deviation 0.50	-0.06 Units on a scale Standard Deviation 1.20
Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score Chest Pain: Week 77	-0.25 Units on a scale Standard Deviation 0.35	-0.21 Units on a scale Standard Deviation 1.03
Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score Chest Pain: Week 78	-0.75 Units on a scale Standard Deviation 0.35	-0.25 Units on a scale Standard Deviation 1.14
Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score Chest Pain: Week 79	0.00 Units on a scale Standard Deviation 0.71	-0.18 Units on a scale Standard Deviation 1.20
Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score Chest Pain: Week 80	-0.25 Units on a scale Standard Deviation 0.35	-0.12 Units on a scale Standard Deviation 0.96
Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score Chest Pain: Week 81	-0.25 Units on a scale Standard Deviation 0.35	-0.25 Units on a scale Standard Deviation 0.89
Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score Chest Pain: Week 82	-0.75 Units on a scale Standard Deviation 0.35	0.00 Units on a scale Standard Deviation 1.25
Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score Chest Pain: Week 83	-0.25 Units on a scale Standard Deviation 0.35	-0.50 Units on a scale Standard Deviation 1.73
Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score Chest Pain: Week 84	0.00 Units on a scale Standard Deviation 0.71	-0.30 Units on a scale Standard Deviation 1.57
Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score Chest Pain: Week 85	-1.00 Units on a scale Standard Deviation NA Only 1 participant.	-0.20 Units on a scale Standard Deviation 1.68
Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score Chest Pain: Week 86	0.00 Units on a scale Standard Deviation NA Only 1 participant.	-0.50 Units on a scale Standard Deviation 1.73
Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score Chest Pain: Week 87	-1.00 Units on a scale Standard Deviation NA Only 1 participant.	0.50 Units on a scale Standard Deviation 0.87
Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score Chest Pain: Week 88	-1.00 Units on a scale Standard Deviation NA Only 1 participant.	0.00 Units on a scale Standard Deviation 0.00
Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score Chest Pain: Week 89	-1.00 Units on a scale Standard Deviation NA Only 1 participant.	0.00 Units on a scale Standard Deviation 0.00
Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score Chest Pain: Week 90	0.00 Units on a scale Standard Deviation NA Only 1 participant.	0.00 Units on a scale Standard Deviation 0.00
Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score Chest Pain: Week 91	0.00 Units on a scale Standard Deviation NA Only 1 participant.	0.00 Units on a scale Standard Deviation 0.00
Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score Chest Pain: Week 92	—	0.00 Units on a scale Standard Deviation 0.00
Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score Chest Pain: Week 93	—	0.00 Units on a scale Standard Deviation 0.00
Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score Chest Pain: Week 94	—	1.00 Units on a scale Standard Deviation NA Only 1 participant.
Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score Chest Pain: Week 95	—	0.50 Units on a scale Standard Deviation NA Only 1 participant.
Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score Chest Pain: Time of First Pd	0.28 Units on a scale Standard Deviation 1.06	0.20 Units on a scale Standard Deviation 0.91
Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score Chest Pain: Time of Last Tx Dose	0.17 Units on a scale Standard Deviation 1.17	0.13 Units on a scale Standard Deviation 0.98
Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score Cough: Week 1	-0.08 Units on a scale Standard Deviation 0.74	-0.06 Units on a scale Standard Deviation 0.89
Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score Cough: Week 2	-0.13 Units on a scale Standard Deviation 0.73	-0.08 Units on a scale Standard Deviation 0.90
Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score Cough: Week 3	-0.05 Units on a scale Standard Deviation 0.77	-0.07 Units on a scale Standard Deviation 0.81
Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score Cough: Week 4	-0.11 Units on a scale Standard Deviation 0.89	-0.22 Units on a scale Standard Deviation 0.85
Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score Cough: Week 5	-0.14 Units on a scale Standard Deviation 0.83	-0.33 Units on a scale Standard Deviation 0.89
Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score Cough: Week 6	-0.16 Units on a scale Standard Deviation 0.85	-0.33 Units on a scale Standard Deviation 0.91
Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score Cough: Week 7	-0.22 Units on a scale Standard Deviation 0.89	-0.22 Units on a scale Standard Deviation 0.97
Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score Cough: Week 8	-0.20 Units on a scale Standard Deviation 0.89	-0.28 Units on a scale Standard Deviation 0.98
Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score Cough: Week 9	-0.17 Units on a scale Standard Deviation 0.91	-0.29 Units on a scale Standard Deviation 0.97
Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score Cough: Week 10	-0.22 Units on a scale Standard Deviation 0.95	-0.35 Units on a scale Standard Deviation 1.06
Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score Cough: Week 11	-0.21 Units on a scale Standard Deviation 0.99	-0.33 Units on a scale Standard Deviation 1.02
Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score Cough: Week 12	-0.13 Units on a scale Standard Deviation 1.05	-0.40 Units on a scale Standard Deviation 0.96
Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score Cough: Week 13	-0.24 Units on a scale Standard Deviation 1.05	-0.37 Units on a scale Standard Deviation 1.04
Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score Cough: Week 14	-0.23 Units on a scale Standard Deviation 0.98	-0.34 Units on a scale Standard Deviation 1.03
Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score Cough: Week 15	-0.11 Units on a scale Standard Deviation 1.03	-0.33 Units on a scale Standard Deviation 1.03
Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score Cough: Week 16	-0.20 Units on a scale Standard Deviation 1.05	-0.33 Units on a scale Standard Deviation 1.04
Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score Cough: Week 17	-0.20 Units on a scale Standard Deviation 1.11	-0.31 Units on a scale Standard Deviation 0.99
Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score Cough: Week 18	-0.19 Units on a scale Standard Deviation 1.12	-0.31 Units on a scale Standard Deviation 1.00
Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score Cough: Week 19	-0.25 Units on a scale Standard Deviation 1.07	-0.36 Units on a scale Standard Deviation 1.06
Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score Cough: Week 20	-0.25 Units on a scale Standard Deviation 1.16	-0.39 Units on a scale Standard Deviation 0.99
Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score Cough: Week 21	-0.19 Units on a scale Standard Deviation 1.09	-0.36 Units on a scale Standard Deviation 1.07
Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score Cough: Week 22	-0.29 Units on a scale Standard Deviation 1.11	-0.41 Units on a scale Standard Deviation 1.08
Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score Cough: Week 23	-0.34 Units on a scale Standard Deviation 1.07	-0.44 Units on a scale Standard Deviation 1.04
Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score Cough: Week 24	-0.27 Units on a scale Standard Deviation 0.96	-0.29 Units on a scale Standard Deviation 1.13
Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score Cough: Week 25	-0.24 Units on a scale Standard Deviation 1.11	-0.27 Units on a scale Standard Deviation 1.10
Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score Cough: Week 26	-0.25 Units on a scale Standard Deviation 1.16	-0.22 Units on a scale Standard Deviation 1.22
Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score Cough: Week 27	-0.19 Units on a scale Standard Deviation 0.99	-0.32 Units on a scale Standard Deviation 1.11
Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score Cough: Week 28	-0.19 Units on a scale Standard Deviation 1.04	-0.32 Units on a scale Standard Deviation 1.12
Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score Cough: Week 29	-0.25 Units on a scale Standard Deviation 1.13	-0.34 Units on a scale Standard Deviation 1.11
Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score Cough: Week 30	-0.08 Units on a scale Standard Deviation 1.12	-0.34 Units on a scale Standard Deviation 1.00
Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score Cough: Week 31	-0.13 Units on a scale Standard Deviation 1.13	-0.37 Units on a scale Standard Deviation 0.99
Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score Cough: Week 32	0.01 Units on a scale Standard Deviation 1.09	-0.45 Units on a scale Standard Deviation 0.94
Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score Cough: Week 33	0.05 Units on a scale Standard Deviation 1.17	-0.44 Units on a scale Standard Deviation 0.99
Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score Cough: Week 34	-0.10 Units on a scale Standard Deviation 1.09	-0.29 Units on a scale Standard Deviation 1.02
Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score Cough: Week 35	-0.27 Units on a scale Standard Deviation 1.05	-0.32 Units on a scale Standard Deviation 0.99
Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score Cough: Week 36	0.01 Units on a scale Standard Deviation 1.10	-0.31 Units on a scale Standard Deviation 0.99
Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score Cough: Week 37	-0.11 Units on a scale Standard Deviation 1.16	-0.37 Units on a scale Standard Deviation 1.01
Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score Cough: Week 38	0.02 Units on a scale Standard Deviation 1.03	-0.31 Units on a scale Standard Deviation 1.03
Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score Cough: Week 39	0.02 Units on a scale Standard Deviation 1.19	-0.33 Units on a scale Standard Deviation 0.98
Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score Cough: Week 40	-0.10 Units on a scale Standard Deviation 1.15	-0.35 Units on a scale Standard Deviation 1.07
Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score Cough: Week 41	-0.27 Units on a scale Standard Deviation 1.10	-0.30 Units on a scale Standard Deviation 1.09
Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score Cough: Week 42	-0.31 Units on a scale Standard Deviation 1.04	-0.31 Units on a scale Standard Deviation 1.04
Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score Cough: Week 43	-0.20 Units on a scale Standard Deviation 1.04	-0.37 Units on a scale Standard Deviation 0.98
Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score Cough: Week 44	0.00 Units on a scale Standard Deviation 1.04	-0.36 Units on a scale Standard Deviation 1.03
Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score Cough: Week 45	-0.18 Units on a scale Standard Deviation 1.14	-0.41 Units on a scale Standard Deviation 1.04
Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score Cough: Week 46	-0.25 Units on a scale Standard Deviation 1.04	-0.34 Units on a scale Standard Deviation 1.17
Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score Cough: Week 47	-0.43 Units on a scale Standard Deviation 1.09	-0.29 Units on a scale Standard Deviation 1.17
Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score Cough: Week 48	-0.26 Units on a scale Standard Deviation 1.16	-0.38 Units on a scale Standard Deviation 1.08
Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score Cough: Week 49	-0.50 Units on a scale Standard Deviation 1.07	-0.40 Units on a scale Standard Deviation 1.10
Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score Cough: Week 50	-0.37 Units on a scale Standard Deviation 0.84	-0.40 Units on a scale Standard Deviation 1.06
Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score Cough: Week 51	-0.45 Units on a scale Standard Deviation 1.16	-0.15 Units on a scale Standard Deviation 1.10
Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score Cough: Week 52	-0.29 Units on a scale Standard Deviation 1.07	-0.10 Units on a scale Standard Deviation 1.17
Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score Cough: Week 53	-0.24 Units on a scale Standard Deviation 1.21	-0.13 Units on a scale Standard Deviation 1.17
Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score Cough: Week 54	-0.27 Units on a scale Standard Deviation 1.10	-0.16 Units on a scale Standard Deviation 1.15
Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score Cough: Week 55	-0.10 Units on a scale Standard Deviation 1.15	-0.35 Units on a scale Standard Deviation 1.13
Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score Cough: Week 56	-0.30 Units on a scale Standard Deviation 1.14	-0.26 Units on a scale Standard Deviation 1.17
Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score Cough: Week 57	-0.41 Units on a scale Standard Deviation 0.92	-0.25 Units on a scale Standard Deviation 1.10
Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score Cough: Week 58	-0.17 Units on a scale Standard Deviation 1.05	-0.45 Units on a scale Standard Deviation 0.96
Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score Cough: Week 59	-0.31 Units on a scale Standard Deviation 0.93	-0.50 Units on a scale Standard Deviation 1.02
Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score Cough: Week 60	-0.55 Units on a scale Standard Deviation 1.04	-0.52 Units on a scale Standard Deviation 1.03
Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score Cough: Week 61	-0.23 Units on a scale Standard Deviation 1.15	-0.38 Units on a scale Standard Deviation 1.07
Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score Cough: Week 62	0.04 Units on a scale Standard Deviation 1.03	-0.53 Units on a scale Standard Deviation 1.15
Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score Cough: Week 63	-0.29 Units on a scale Standard Deviation 1.18	-0.57 Units on a scale Standard Deviation 1.10
Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score Cough: Week 64	-0.45 Units on a scale Standard Deviation 1.04	-0.49 Units on a scale Standard Deviation 1.01
Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score Cough: Week 65	-0.61 Units on a scale Standard Deviation 0.96	-0.39 Units on a scale Standard Deviation 0.94
Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score Cough: Week 66	-0.17 Units on a scale Standard Deviation 0.82	-0.43 Units on a scale Standard Deviation 1.18
Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score Cough: Week 67	-0.64 Units on a scale Standard Deviation 1.07	-0.47 Units on a scale Standard Deviation 0.84
Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score Cough: Week 68	-0.75 Units on a scale Standard Deviation 0.88	-0.35 Units on a scale Standard Deviation 1.04
Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score Cough: Week 69	-0.57 Units on a scale Standard Deviation 1.10	-0.53 Units on a scale Standard Deviation 0.90
Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score Cough: Week 70	-0.83 Units on a scale Standard Deviation 0.93	-0.43 Units on a scale Standard Deviation 0.98
Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score Cough: Week 71	-0.90 Units on a scale Standard Deviation 0.89	-0.56 Units on a scale Standard Deviation 1.04
Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score Cough: Week 72	-1.25 Units on a scale Standard Deviation 0.50	-0.72 Units on a scale Standard Deviation 1.15
Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score Cough: Week 73	-0.63 Units on a scale Standard Deviation 1.11	-0.77 Units on a scale Standard Deviation 1.00
Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score Cough: Week 74	-0.63 Units on a scale Standard Deviation 1.11	-0.54 Units on a scale Standard Deviation 0.94
Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score Cough: Week 75	-0.63 Units on a scale Standard Deviation 1.11	-0.67 Units on a scale Standard Deviation 1.00
Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score Cough: Week 76	-1.00 Units on a scale Standard Deviation 1.00	-0.65 Units on a scale Standard Deviation 1.22
Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score Cough: Week 77	-0.50 Units on a scale Standard Deviation 0.71	-0.82 Units on a scale Standard Deviation 1.21
Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score Cough: Week 78	-1.00 Units on a scale Standard Deviation 0.00	-0.57 Units on a scale Standard Deviation 1.04
Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score Cough: Week 79	-0.25 Units on a scale Standard Deviation 0.35	-0.64 Units on a scale Standard Deviation 1.23
Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score Cough: Week 80	-0.50 Units on a scale Standard Deviation 0.71	-1.04 Units on a scale Standard Deviation 1.11
Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score Cough: Week 81	-0.50 Units on a scale Standard Deviation 0.71	-0.79 Units on a scale Standard Deviation 1.05
Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score Cough: Week 82	-0.50 Units on a scale Standard Deviation 0.71	-0.89 Units on a scale Standard Deviation 1.27
Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score Cough: Week 83	-1.00 Units on a scale Standard Deviation 0.00	0.13 Units on a scale Standard Deviation 1.03
Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score Cough: Week 84	-0.50 Units on a scale Standard Deviation 0.71	-0.20 Units on a scale Standard Deviation 1.04
Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score Cough: Week 85	0.00 Units on a scale Standard Deviation NA Only 1 participant.	0.00 Units on a scale Standard Deviation 0.87
Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score Cough: Week 86	0.00 Units on a scale Standard Deviation NA Only 1 participant.	-0.38 Units on a scale Standard Deviation 0.48
Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score Cough: Week 87	0.00 Units on a scale Standard Deviation NA Only 1 participant.	-0.83 Units on a scale Standard Deviation 0.58
Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score Cough: Week 88	0.00 Units on a scale Standard Deviation NA Only 1 participant.	-0.88 Units on a scale Standard Deviation 0.48
Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score Cough: Week 89	0.00 Units on a scale	0.00 Units on a scale Standard Deviation 0.71
Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score Cough: Week 90	0.00 Units on a scale	0.25 Units on a scale Standard Deviation 1.06
Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score Cough: Week 92	—	0.50 Units on a scale Standard Deviation 0.71
Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score Cough: Week 93	—	0.50 Units on a scale Standard Deviation 0.71
Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score Cough: Week 94	—	0.50 Units on a scale Standard Deviation NA Only 1 participant.
Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score Cough: Week 95	—	0.00 Units on a scale Standard Deviation NA Only 1 participant.
Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score Cough: Time of First Pd	-0.08 Units on a scale Standard Deviation 1.12	-0.45 Units on a scale Standard Deviation 0.93
Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score Cough: Time of Last Tx Dose	-0.15 Units on a scale Standard Deviation 0.95	-0.29 Units on a scale Standard Deviation 0.91
Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score Dyspnoea: Week 1	0.20 Units on a scale Standard Deviation 0.82	0.16 Units on a scale Standard Deviation 0.81
Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score Dyspnoea: Week 2	0.11 Units on a scale Standard Deviation 0.76	0.15 Units on a scale Standard Deviation 0.82
Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score Dyspnoea: Week 3	0.10 Units on a scale Standard Deviation 0.71	0.12 Units on a scale Standard Deviation 0.70
Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score Dyspnoea: Week 4	0.21 Units on a scale Standard Deviation 0.84	0.17 Units on a scale Standard Deviation 0.95
Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score Dyspnoea: Week 5	0.22 Units on a scale Standard Deviation 0.82	0.17 Units on a scale Standard Deviation 0.91
Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score Dyspnoea: Week 6	0.23 Units on a scale Standard Deviation 0.82	0.16 Units on a scale Standard Deviation 0.95
Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score Dyspnoea: Week 7	0.30 Units on a scale Standard Deviation 0.93	0.25 Units on a scale Standard Deviation 0.92
Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score Dyspnoea: Week 8	0.35 Units on a scale Standard Deviation 0.87	0.24 Units on a scale Standard Deviation 0.96
Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score Dyspnoea: Week 9	0.34 Units on a scale Standard Deviation 0.89	0.17 Units on a scale Standard Deviation 0.91
Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score Dyspnoea: Week 10	0.46 Units on a scale Standard Deviation 0.93	0.16 Units on a scale Standard Deviation 0.92
Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score Dyspnoea: Week 11	0.39 Units on a scale Standard Deviation 1.01	0.26 Units on a scale Standard Deviation 0.96
Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score Dyspnoea: Week 43	0.32 Units on a scale Standard Deviation 0.89	0.22 Units on a scale Standard Deviation 0.90
Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score Dyspnoea: Week 44	0.58 Units on a scale Standard Deviation 0.83	0.23 Units on a scale Standard Deviation 0.92
Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score Dyspnoea: Week 45	0.49 Units on a scale Standard Deviation 0.96	0.21 Units on a scale Standard Deviation 0.90
Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score Dyspnoea: Week 46	0.55 Units on a scale Standard Deviation 1.02	0.23 Units on a scale Standard Deviation 0.89
Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score Dyspnoea: Week 47	0.53 Units on a scale Standard Deviation 1.09	0.14 Units on a scale Standard Deviation 0.90
Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score Dyspnoea: Week 48	0.55 Units on a scale Standard Deviation 0.96	0.14 Units on a scale Standard Deviation 0.85
Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score Dyspnoea: Week 49	0.63 Units on a scale Standard Deviation 1.04	0.16 Units on a scale Standard Deviation 0.90
Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score Dyspnoea: Week 50	0.52 Units on a scale Standard Deviation 0.98	0.24 Units on a scale Standard Deviation 0.94
Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score Dyspnoea: Week 51	0.67 Units on a scale Standard Deviation 1.04	0.30 Units on a scale Standard Deviation 0.97
Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score Dyspnoea: Week 52	0.72 Units on a scale Standard Deviation 1.02	0.27 Units on a scale Standard Deviation 1.02
Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score Dyspnoea: Week 53	0.81 Units on a scale Standard Deviation 1.06	0.22 Units on a scale Standard Deviation 0.95
Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score Dyspnoea: Week 54	0.82 Units on a scale Standard Deviation 1.06	0.23 Units on a scale Standard Deviation 0.95
Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score Dyspnoea: Week 55	0.77 Units on a scale Standard Deviation 1.17	0.16 Units on a scale Standard Deviation 0.99
Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score Dyspnoea: Week 56	0.84 Units on a scale Standard Deviation 1.15	0.18 Units on a scale Standard Deviation 0.95
Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score Dyspnoea: Week 57	0.68 Units on a scale Standard Deviation 1.16	0.11 Units on a scale Standard Deviation 0.91
Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score Dyspnoea: Week 58	0.77 Units on a scale Standard Deviation 1.06	0.16 Units on a scale Standard Deviation 0.86
Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score Dyspnoea: Week 59	0.66 Units on a scale Standard Deviation 0.90	0.07 Units on a scale Standard Deviation 0.85
Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score Dyspnoea: Week 60	0.73 Units on a scale Standard Deviation 0.96	0.27 Units on a scale Standard Deviation 0.94
Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score Dyspnoea: Week 61	0.85 Units on a scale Standard Deviation 1.04	0.23 Units on a scale Standard Deviation 0.90
Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score Dyspnoea: Week 62	0.95 Units on a scale Standard Deviation 1.05	0.16 Units on a scale Standard Deviation 0.92
Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score Dyspnoea: Week 63	0.67 Units on a scale Standard Deviation 1.01	0.27 Units on a scale Standard Deviation 0.95
Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score Dyspnoea: Week 64	0.46 Units on a scale Standard Deviation 0.78	0.14 Units on a scale Standard Deviation 0.93
Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score Dyspnoea: Week 65	0.40 Units on a scale Standard Deviation 0.66	0.12 Units on a scale Standard Deviation 0.95
Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score Dyspnoea: Week 66	0.67 Units on a scale Standard Deviation 0.74	0.16 Units on a scale Standard Deviation 0.94
Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score Dyspnoea: Week 67	0.37 Units on a scale Standard Deviation 0.76	0.26 Units on a scale Standard Deviation 1.01
Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score Dyspnoea: Week 68	0.47 Units on a scale Standard Deviation 0.80	0.25 Units on a scale Standard Deviation 1.03
Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score Dyspnoea: Week 69	0.43 Units on a scale Standard Deviation 0.80	0.16 Units on a scale Standard Deviation 1.11
Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score Dyspnoea: Week 70	0.33 Units on a scale Standard Deviation 0.83	0.07 Units on a scale Standard Deviation 0.89
Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score Dyspnoea: Week 71	0.40 Units on a scale Standard Deviation 0.91	0.13 Units on a scale Standard Deviation 0.89
Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score Dyspnoea: Week 72	-0.05 Units on a scale Standard Deviation 0.25	0.06 Units on a scale Standard Deviation 0.91
Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score Dyspnoea: Week 73	0.45 Units on a scale Standard Deviation 1.04	0.09 Units on a scale Standard Deviation 0.99
Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score Dyspnoea: Week 74	0.50 Units on a scale Standard Deviation 1.01	0.27 Units on a scale Standard Deviation 1.19
Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score Dyspnoea: Week 75	0.55 Units on a scale Standard Deviation 0.97	0.45 Units on a scale Standard Deviation 1.31
Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score Dyspnoea: Week 76	-0.07 Units on a scale Standard Deviation 0.12	0.02 Units on a scale Standard Deviation 1.10
Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score Dyspnoea: Week 77	0.00 Units on a scale Standard Deviation 0.00	0.09 Units on a scale Standard Deviation 1.17
Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score Dyspnoea: Week 78	0.00 Units on a scale Standard Deviation 0.00	0.03 Units on a scale Standard Deviation 1.19
Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score Dyspnoea: Week 79	0.00 Units on a scale Standard Deviation 0.00	0.19 Units on a scale Standard Deviation 1.18
Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score Dyspnoea: Week 80	0.10 Units on a scale Standard Deviation 0.14	-0.26 Units on a scale Standard Deviation 0.80
Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score Dyspnoea: Week 81	0.10 Units on a scale Standard Deviation 0.14	-0.17 Units on a scale Standard Deviation 1.15
Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score Dyspnoea: Week 82	0.00 Units on a scale Standard Deviation 0.00	0.18 Units on a scale Standard Deviation 1.54
Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score Dyspnoea: Week 83	0.00 Units on a scale Standard Deviation 0.00	0.45 Units on a scale Standard Deviation 1.22
Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score Dyspnoea: Week 84	0.00 Units on a scale Standard Deviation 0.00	0.60 Units on a scale Standard Deviation 1.10
Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score Dyspnoea: Week 85	0.20 Units on a scale Standard Deviation NA Only 1 participant.	0.32 Units on a scale Standard Deviation 1.53
Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score Dyspnoea: Week 86	0.00 Units on a scale Standard Deviation NA Only 1 participant.	-0.15 Units on a scale Standard Deviation 0.34
Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score Dyspnoea: Week 87	0.20 Units on a scale Standard Deviation NA Only 1 participant.	-0.47 Units on a scale Standard Deviation 0.23
Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score Dyspnoea: Week 88	0.20 Units on a scale Standard Deviation NA Only 1 participant.	-0.70 Units on a scale Standard Deviation 0.20
Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score Dyspnoea: Week 89	0.20 Units on a scale Standard Deviation NA Only 1 participant.	-0.20 Units on a scale Standard Deviation 0.57
Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score Dyspnoea: Week 90	0.20 Units on a scale Standard Deviation NA Only 1 participant.	-0.50 Units on a scale Standard Deviation 0.14
Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score Dyspnoea: Week 91	0.00 Units on a scale Standard Deviation NA Only 1 participant.	-0.50 Units on a scale Standard Deviation 0.14
Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score Dyspnoea: Week 92	—	-0.70 Units on a scale Standard Deviation 0.14
Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score Dyspnoea: Week 93	—	-0.40 Units on a scale Standard Deviation 0.28
Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score Dyspnoea: Week 94	—	-0.80 Units on a scale Standard Deviation NA Only 1 participant.
Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score Dyspnoea: Week 95	—	-1.00 Units on a scale Standard Deviation NA Only 1 participant.
Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score Dyspnoea: Time of First Pd	0.58 Units on a scale Standard Deviation 0.99	0.40 Units on a scale Standard Deviation 1.06
Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score Dyspnoea: Time of Last Tx Dose	0.47 Units on a scale Standard Deviation 0.95	0.18 Units on a scale Standard Deviation 0.94
Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score Chest Pain: Week 1	0.20 Units on a scale Standard Deviation 0.83	0.30 Units on a scale Standard Deviation 0.88
Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score Chest Pain: Week 2	-0.01 Units on a scale Standard Deviation 0.88	0.21 Units on a scale Standard Deviation 0.85
Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score Chest Pain: Week 3	-0.05 Units on a scale Standard Deviation 0.92	0.06 Units on a scale Standard Deviation 0.95
Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score Chest Pain: Week 4	0.03 Units on a scale Standard Deviation 0.91	0.03 Units on a scale Standard Deviation 0.93
Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score Chest Pain: Week 5	-0.02 Units on a scale Standard Deviation 0.93	-0.01 Units on a scale Standard Deviation 0.88
Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score Chest Pain: Week 6	-0.05 Units on a scale Standard Deviation 0.88	-0.02 Units on a scale Standard Deviation 0.92
Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score Chest Pain: Week 7	0.07 Units on a scale Standard Deviation 1.00	-0.04 Units on a scale Standard Deviation 1.00
Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score Chest Pain: Week 8	0.03 Units on a scale Standard Deviation 0.94	-0.07 Units on a scale Standard Deviation 1.02
Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score Chest Pain: Week 9	0.06 Units on a scale Standard Deviation 1.00	-0.03 Units on a scale Standard Deviation 1.03
Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score Chest Pain: Week 10	0.03 Units on a scale Standard Deviation 1.02	0.02 Units on a scale Standard Deviation 1.05
Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score Chest Pain: Week 11	0.02 Units on a scale Standard Deviation 0.96	0.04 Units on a scale Standard Deviation 1.09
Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score Chest Pain: Week 12	-0.02 Units on a scale Standard Deviation 0.96	-0.01 Units on a scale Standard Deviation 1.02
Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score Chest Pain: Week 13	-0.05 Units on a scale Standard Deviation 1.02	0.05 Units on a scale Standard Deviation 0.97
Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score Chest Pain: Week 14	-0.07 Units on a scale Standard Deviation 1.12	0.06 Units on a scale Standard Deviation 1.06
Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score Chest Pain: Week 15	0.13 Units on a scale Standard Deviation 1.16	0.08 Units on a scale Standard Deviation 0.94
Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score Chest Pain: Week 16	0.02 Units on a scale Standard Deviation 1.08	0.08 Units on a scale Standard Deviation 1.04
Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score Chest Pain: Week 17	0.02 Units on a scale Standard Deviation 1.08	0.00 Units on a scale Standard Deviation 1.08
Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score Chest Pain: Week 18	-0.06 Units on a scale Standard Deviation 1.11	0.12 Units on a scale Standard Deviation 1.07
Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score Chest Pain: Week 19	-0.15 Units on a scale Standard Deviation 1.12	0.02 Units on a scale Standard Deviation 1.01
Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score Chest Pain: Week 20	-0.02 Units on a scale Standard Deviation 1.22	-0.01 Units on a scale Standard Deviation 1.03
Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score Chest Pain: Week 21	0.03 Units on a scale Standard Deviation 1.28	0.01 Units on a scale Standard Deviation 1.03
Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score Chest Pain: Week 22	0.04 Units on a scale Standard Deviation 1.21	0.02 Units on a scale Standard Deviation 1.02
Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score Chest Pain: Week 23	-0.08 Units on a scale Standard Deviation 1.14	0.04 Units on a scale Standard Deviation 0.96
Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score Chest Pain: Week 24	-0.02 Units on a scale Standard Deviation 1.16	0.09 Units on a scale Standard Deviation 0.99
Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score Chest Pain: Week 25	0.05 Units on a scale Standard Deviation 1.24	0.14 Units on a scale Standard Deviation 1.03
Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score Chest Pain: Week 26	-0.05 Units on a scale Standard Deviation 1.14	0.09 Units on a scale Standard Deviation 1.00
Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score Chest Pain: Week 27	0.04 Units on a scale Standard Deviation 1.17	0.04 Units on a scale Standard Deviation 1.01
Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score Chest Pain: Week 28	0.24 Units on a scale Standard Deviation 1.18	0.03 Units on a scale Standard Deviation 0.93
Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score Chest Pain: Week 29	0.06 Units on a scale Standard Deviation 1.29	0.04 Units on a scale Standard Deviation 0.95
Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score Chest Pain: Week 30	0.01 Units on a scale Standard Deviation 1.37	0.04 Units on a scale Standard Deviation 0.97
Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score Chest Pain: Week 31	0.02 Units on a scale Standard Deviation 1.09	0.05 Units on a scale Standard Deviation 0.88
Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score Chest Pain: Week 32	0.21 Units on a scale Standard Deviation 1.21	-0.01 Units on a scale Standard Deviation 0.98
Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score Chest Pain: Week 33	0.04 Units on a scale Standard Deviation 1.17	0.03 Units on a scale Standard Deviation 0.92
Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score Chest Pain: Week 34	0.21 Units on a scale Standard Deviation 1.27	0.11 Units on a scale Standard Deviation 0.99
Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score Chest Pain: Week 35	0.33 Units on a scale Standard Deviation 1.30	0.11 Units on a scale Standard Deviation 0.98
Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score Chest Pain: Week 36	0.15 Units on a scale Standard Deviation 1.07	0.17 Units on a scale Standard Deviation 1.04
Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score Chest Pain: Week 37	0.15 Units on a scale Standard Deviation 1.21	0.06 Units on a scale Standard Deviation 0.94
Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score Chest Pain: Week 38	0.12 Units on a scale Standard Deviation 1.16	0.04 Units on a scale Standard Deviation 1.03
Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score Chest Pain: Week 39	0.20 Units on a scale Standard Deviation 1.23	0.13 Units on a scale Standard Deviation 1.01
Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score Chest Pain: Week 40	0.15 Units on a scale Standard Deviation 1.31	0.04 Units on a scale Standard Deviation 0.96
Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score Chest Pain: Week 41	-0.05 Units on a scale Standard Deviation 1.06	0.09 Units on a scale Standard Deviation 1.03
Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score Chest Pain: Week 42	-0.06 Units on a scale Standard Deviation 1.07	0.03 Units on a scale Standard Deviation 1.02
Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score Chest Pain: Week 43	-0.22 Units on a scale Standard Deviation 0.82	0.13 Units on a scale Standard Deviation 1.02
Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score Chest Pain: Week 44	-0.10 Units on a scale Standard Deviation 1.29	0.10 Units on a scale Standard Deviation 1.04
Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score Dyspnoea: Week 12	0.38 Units on a scale Standard Deviation 0.96	0.22 Units on a scale Standard Deviation 0.90
Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score Dyspnoea: Week 13	0.34 Units on a scale Standard Deviation 0.96	0.30 Units on a scale Standard Deviation 1.02
Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score Dyspnoea: Week 14	0.44 Units on a scale Standard Deviation 0.95	0.22 Units on a scale Standard Deviation 0.99
Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score Dyspnoea: Week 15	0.45 Units on a scale Standard Deviation 0.94	0.19 Units on a scale Standard Deviation 0.95
Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score Dyspnoea: Week 16	0.37 Units on a scale Standard Deviation 1.06	0.26 Units on a scale Standard Deviation 1.02

SECONDARY outcome

Timeframe: Predose (Prd; 0 hour [h]) on D1 of Cy 2,3,4,8,16 (Cy length=21 days) and thereafter on D1 of every 8th cycle (up to approximately 25 months)